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Abstract 
Dengue (DENV) virus is a positive-strand RNA flavivirus that affects 100-200 million 
people worldwide annually. It is currently the most important arbovirus with 2.5 billion 
people at risk of disease. The envelope protein (E) of DENV is comprised of three 
domains, I, II, and III. The stem-anchor region connected to DIII contains two helices 
(membrane proximal and membrane distal) separated by a CS (conserved sequence) 
and followed by two membrane-spanning domains. It is believed that the two helices 
comprising the stem constrain monomeric E to lie flat against the viral envelope in the 
mature virion. Upon a low pH-induced conformational change, E shifts vertically away 
from the viral envelope, exposing the class II fusion peptide in domain II allowing it to 
interact with the target host cell membrane. Within the membrane-proximal helix there 
are a series of highly conserved, hydrophobic aromatic residues at positions F422, 
F429, F440, Y444 and F448, which all lie on one side of the helix. We examined whether 
these residues play a role in structural changes of E and localisation within the cell by 
mutagenesis. Recombinant constructs of prM and E containing the mutants F422A/Y, 
F429A/Y, F440A/Y, Y444A/F and F448A/Y were generated and, following transfection 
were tested for expression, heterodimeric association with prM, and cytoplasmic and cell 
surface expression via immunofluorescence. All constructs expressed protein and 
retained antibody specificity. The F422A resulted in reduced expression seen with 
immunofluorescence while the other mutants did not.  Ultimately, fusion assays should 
be performed on these constructs to determine whether or not these mutants are 
capable of mediating membrane fusion. 
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CHAPTER 1 
INTRODUCTION 
1.1. Dengue Fever and Global Prevalence 
Dengue virus belongs to the family Flaviviridae, a group of positive-strand RNA viruses, 
which are primarily spread through arthropod vectors. It is closely related to at least 70 
other species such as Hepatitis C, West Nile, Yellow Fever, Japanese and Tick-Borne 
Encephalitis [1]. Dengue Fever (DF) and the associated syndromes Dengue 
Haemorrhagic Fever (DHF) and Dengue Shock Syndrome (DSS) are second only to 
malaria in terms of the number of people that become infected annually. Carried by 
Aedes aegypti, there is an estimated 50-100 million cases of which, 250,000-500,000 
are DHF resulting in 30,000 to 50,000 deaths per year [2, 3]. Two and a half billion 
people are exposed annually and dengue infection is the leading cause for 
hospitalization in at least eight South-East Asia countries [4]. Infection rates have 
increased in the last few decades because of the geographical expansion of Aedes 
agypti and Aedes albopictus [5]. This situation is likely to become worse with the effects 
of global warming increasing the territorial spread of these mosquitoes. In 1970 there 
were seven countries that had endemic Dengue fever, now there are 60 [6]. Australia 
has seen infections since 1873 and is interdependent on the infection rate in Asia and 
the Pacific [7]. In December 2007, warnings were reported in Australia of the spread of 
mosquito-borne diseases, specifically of Dengue, Ross River fever and Malaria because 
the tropical zone has increased two degrees of latitude in the last 25 years [8]. In 
February 2011, there were 39 cases of DENV-2 in East Innisfail, QLD [9].  
 
Figure 1. Distribution of Dengue Fever globally as of 2011 [10]. Global evidence consensus of risk 
and burden of dengue from complete absence to complete presence.  
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While DF is a mild, febrile illness, it can cause large-scale societal hardship when 
periodic epidemics break out in equatorial regions. In 2007, Brazil reported 560,000 
cases (with 82,000 in Sao Paulo), Indonesia 134,847 and 80,000 in Vietnam [6]. Dengue 
fever causes severe headache and eye pain, joint pain (it is often called “bone break 
fever”), rash, mild bleeding manifestations and low white cell count. DHF and Dengue 
Shock Syndrome (DSS) on the other hand can be severe and has a 2.5% chance of 
fatality, usually in children and immuno-compromised adults and, if survived, can take 
weeks to recover from. If modern health care is not provided, case fatality can reach 
20% [8]. Historically children have borne the brunt of the disease burden but this age 
profile is changing in Asia and Latin America where adults are increasingly being 
affected [11]. DENV has 4 serotypes 1-4 and multiple genotypes. If a patient has been 
affected by one serotype, this will most likely not confer immunity to another and in fact 
may lead to more severe antibody-enhancement induced DHF or DSS, as does co-
infection with one or more serotypes [5, 12].  
Due to the geographic spread, the global number of infections and ignorance of the 
disease, dengue has become an important re-emerging virus [13]. There are currently no 
vaccines or therapeutics for dengue infections; however, there are currently five in 
clinical trials [14]. Our laboratory is engaged in research to accurately elucidate the 
structural relationships between the viral proteins and the cellular host receptors. By 
increasing our knowledge of this relationship we hope to design anti-viral therapies that 
can combat Dengue infection and/or prevent transmission. 
 
1.2. Antibody-Dependent Enhancement and Vaccine development 
One of the most successful vaccines in providing immunity is for Yellow Fever (YF), 
which has a highly related genome and antigenic structure to Dengue. The diversity and 
pathogenesis is very different as there are four serotypes (1-4) for dengue [7]. For 
reasons yet unknown, when one has been infected with a previous serotype and is co-
infected or subsequently infected with a different serotype, the severity of the disease 
may be higher. This is called antibody-dependent enhancement (ADE), as the primary 
antibodies do not neutralize the subsequent virus. Cross-reactive memory T cells appear 
to increase cytokine production when exposed to the secondary serotype [15]. In 
contrast to the “reassuring dogma that infectious diseases evolve inexorably toward 
commensalism and reduced virulence” [16], Dengue offers no cross-reactive immunity 
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and re-infection is more severe. This feature has hindered vaccine development. A 
vaccine has been a WHO priority for three decades now to control dengue [11]. There 
are several types of vaccines in development including a YF-DF chimera, a DNA 
vaccine, a recombinant viral vector and subviral particles with Dengue envelope proteins 
[6]. Sanofi-Pasteur has created a tetravalent vaccine called ChimeriVax™, which has a 
YF backbone (C and NS proteins) and prME of all four serotypes, which is in Phase III 
clinical trials [14, 17]. Unfortunately, ADE events may only present in phase IV clinical 
trials or post-market. 
 
 1.3. Dengue virus structure 
DENV is a positive strand RNA virus, 10.7 kB in length with the following genome 
organization: 5’ UTR-C-prM-E-NS1-NS2B-NS3-NS4A-NS4B-NS5-UTR-3’. The dengue 
genome translates to a single 3391 amino acid polypeptide, which is co-translationally 
processed by viral and cellular proteases, generating three structural and 7 non-
structural proteins (figure 2) [18].  
 
Figure 2. Dengue genome and polyprotein structure. Dengue genome structure is a single open reading 
frame, 10.7kB in length displaying the three structural and seven non-structural proteins. The positive sense 
RNA strand has 5’ cap and poly-A tail elements. The 3391 amino acid polypeptide is co- and post-
translationally processed by viral and cellular proteases displayed. This figure displays the single polyprotein 
configuration in the endoplasmic reticulum before transcriptional cleavage by viral NS3/2B, cellular furin and 
signalase. [19]. 
 
The structural proteins are comprised of prM, the membrane precursor, M the membrane 
protein, C the capsid protein, and E the envelope protein. The C protein is 100 amino 
acids in length, M is 75 (8 kDa) and E is 495 (~50 kDa) [20]. The virion displays 
icosahedral symmetry with a spherical nucleocapsid 40-50 nM in diameter. The E 
glycoprotein is responsible for cell association and binding. DC-SIGN and heparin sulfate 
are considered to be binding candidates and are thought to adhere the virus to the cell 
before higher affinity receptors engage [21].  
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1.4. Dengue virus cellular pathway 
The virus enters by cell surface binding by receptor-mediated endocytosis [22]. Cellular 
binding receptors have not been completely characterised but include attachment 
receptors DC-SIGN, heparin sulfate, and immunoglobulin Fc receptors as well as 
possibly integrin and CD14 or a similar molecule [1]. After uptake of the virion into the 
endosome following endocytosis, the acidic pH of the endosome induces structural 
alterations in E that lead to membrane fusion and the release of the nucleocapsid into 
the cytoplasm. After un-coating, the plus-stranded RNA genome is translated to initiate 
virus replication and subsequent polyprotein synthesis and processing. Virus assembly 
occurs in the endoplasmic reticulum (ER) and leads to the formation of immature (prM-
containing) particles that are transported through the exocytic pathway (figure 3). The 
capsid protein assembles with RNA on the cystolic face of the ER membrane, which 
then buds through the membrane, acquiring an envelope of lipids along with prM and E 
proteins [23].  
 
 
Figure 3.  Dengue virus life cycle. Virus entry occurs by receptor-mediated endocytosis. The acidic 
pH in the endosome induces structural alterations in E that lead to membrane fusion and the release of the 
nucleocapsid into the cytoplasm. After uncoating, the plus-stranded RNA genome is translated to initiate 
virus replication. Virus assembly occurs in the endoplasmic reticulum (ER) and leads to the formation of 
immature (prM-containing) particles that are transported through the exocytic pathway. The acidic pH in the 
trans-Golgi network (TGN) causes an irreversible conformational change in the prM–E complex that is 
required for the maturation cleavage by cellular furin. Mature infectious particles are released by exocytosis 
[24].  
 
The acidic pH of the trans-Golgi network (TGN) causes a low pH-induced irreversible 
conformational change with E protein subunits rearranging from homodimers to 
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monomers and then homotrimers in a three-fold axis of symmetry [25-27]. This 
conformational change in the prM-E complex is required for cleavage by cellular furin, 
maturation of the viral particle and subsequent release. 
 
1.5. Immature versus mature viral particles: the envelope protein 
Dengue virions transition between a number of structural forms during maturation and 
two of these forms have been imaged by cryo-EM; the immature and mature form of E. 
In immature fusion-incompetent viruses, E forms a stable heterodimeric complex with the 
chaperone prM approximately 15 minutes after synthesis, see figure 2 [21, 28]. These 
immature virions are non-infectious and are not capable of hemagglutination or fusion 
[29]. Subviral particles are also assembled on the ER and consist of only prM, E and 
lipids. They are routinely seen in flaviviral infections. Inefficient cleavage of prM by 
cellular furin occurs regularly resulting in extracellular, partially mature noninfectious 
particles. A recent study showed that as much as 40% of all extracellular DENV particles 
from C6/36 cells are partially immature, which shows that maturation during virus egress 
is rather inefficient [30]. 
 
Figure 4. Mature versus immature prME protein. The heterodimers of prM and E displayed on DENV 
surfaces project in the immature virion; prM protects the fusion peptide (FP) region of E. During viral 
maturation, pr is cleaved from M and the homodimers of E rearrange to lie flat in an icosahedral formation. 
The FP is buried before the active fusion is triggered. M remains associated with the viral membrane [26]. 
 
The trans-Golgi network (TGN) is an acidic environment, in which prM functions to 
protect E’s fusion loop from premature fusion. After processing through the endocytotic 
pathway, furin cleaves the N-terminal pr domain of prM in the late TGN (figure 4). One 
hundred amino acids of prM are released by furin [31]. The cleaved pr domain remains 
temporarily associated with E and is lost as the pH rises through the secretory pathway. 
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This generates fusion-competent mature virus particles [26]. In this mature form at 
neutral pH, E is arranged as homodimers that lie horizontally on the viral membrane in 
30 “rafts” [27]. Each “raft” has three parallel dimers arranged in a herringbone pattern 
with icosahedral symmetry [24, 27, 29]. This scaffold of 90 E homodimers is arranged 
from head to tail and each monomer is anchored via two transmembrane segments [32]. 
The fusion peptide (FP) is embedded in a hydrophobic pocket of the neighboring 
monomer. 
 
   
 
 
Figure 5. Immature to mature virion cryo-EM reconstruction. Immature flavivirus of Dengue-2 at 16-Å 
resolution (left) with heterodimer of prM (green) and E displayed. Domains I, II, and III are color-coded red, 
yellow, and blue respectively. prM protein that caps the trimeric spike is visible. Mature (right) homotrimer 
conformational change after disassociation of pr [29]. 
 
 
 
Figure 6. pH changes and E protein conformation. The spiky, immature virion at pH 7.7 as heterodimer 
pairs. As the protein matures, at pH 6, the protein rearranges to homodimers. Furin cleaves pr from E at pH 
6 although pr stays associated with E to protect it from premature fusion. At pH 7, the mature virion loses its 
association with pr and membrane fusion occurs at pH 6. 
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Figure 7. DENV envelope protein showing domains I, II, and III. Domain I is in red, domain III is in blue 
and domain II is in yellow.  The perforated grey line shows the predicted α-helices, E2 (membrane proximal) 
and E1 (membrane distal) [21]. 
 
The X-ray crystallographic structure of E has been determined [23, 31, 33] and the cryo-
EM structures are displayed in figure 5 [34]. E has twelve strictly conserved cysteines, 
which form six disulfide bridges. The E monomer has three domains referred to as 
domain I (amino acids 1-50, 136-194), domain II (51-135), and domain III (300-395) 
(figures 5 and 7) [5, 18]. Domain III is an immunoglobulin-like domain, domain I is termed 
“central” and domain II is the dimerisation domain [35]. These domains are rich in β-
sheets, typical of all class II fusion proteins [36]. The “dimerisation” domain II of one 
dimer contacts with DI and DIII of its neighbours in a triangulation T=1 orientation [26, 
34]. This involvement stabilizes the E protein dimer. DI and DII are connected by four 
polypeptide strands while DI and DIII are connected by only one [31]. DII also contains 
the internal fusion peptide (FP). Domain I is an eight-stranded β-barrel containing two 
large insertion loops that form the gated finger-like domain. Domain III forms a 10-
stranded β-barrel with an immunoglobulin-like fold and contains the cellular receptor 
binding motifs [37]. Antigenic determinants that respond to neutralizing antibodies are 
also found in this domain [26].  
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As the E protein matures, it rearranges from a spiky, heterodimeric partnering with prM 
in the immature form to homotrimers in the mature form (figure 5). This pH-induced 
maturation begins at around pH 6, as E rearranges to homodimers. Furin cleaves pr 
from E at pH 6 although pr stays associated with E to protect it from premature fusion. At 
pH 7, the mature virion loses its association with pr and membrane fusion occurs at pH 6 
(figure 6). 
1.5. Non-Structural Proteins: NS1, NS2A, NS2B, NS3, NS4A/B, NS5 
There are seven non-structural proteins for Dengue, some of which have known ribbon 
structures (figure 8) [38]. NS3 is a protease-helicase with a chymotrypsin-like serine 
protease as well as a RNA helicase and RTPase/NTPase. NS5, which is the largest 
protein at 104 kDa, is most conserved among serotypes 1-4. It has a methyl-transferase 
domain at its N-terminal end and a RNA-dependent RNA polymerase at its C-terminal 
end [38]. NS1 at 45 kDa is translocated into the lumen of the ER and secreted from the 
cell [39]. It is involved in the viral replication complex and acts in viral defense through 
inhibition of complement activation [40, 41]. NS2A (22 KDa) is part of the replication 
complex [42]. NS 4A/4B (16 KDa/27 KDa) are integral membrane proteins. NS4A 
induces membrane alterations, which are important for viral replication [43]. NS4B has 
been implicated in assisting viral RNA replication through direct interaction with NS3 
[44]. NS4B is also an interferon α/β induced signal transduction blocker [45]. 
 
 
Figure 8. Known ribbon diagrams of Dengue structural and non-structural proteins [38].  
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1.6. Class I fusion  
It is useful to review the well characterised class I fusion machinery of influenza 
hemagglutinin (HA) in comparison to Dengue class II fusion. Class I includes retro-, 
orthomyxo-, paramyxo-, corona- and filoviridae [46]. In class I fusion, exposure to the 
low-pH environment of the endosome or binding to a receptor alters the fusion protein 
conformation so that an N-terminally located fusion peptide (FP) extends into the host 
membrane. The protein then trimerizes, critically instigated by the stem region, resulting 
in a helical hairpin structure, which brings the two membranes into close proximity [12, 
46]. This hairpin structure or hemifusion stalk forms a mixture of the outer leaflets of the 
lipid membranes [29]. Finally, the fusion peptide rearranges completely so that the FP 
and the transmembrane domains are anti-parallel to each other but in the same 
membrane (figure 9). 
The trimeric post-fusion structure of HA is typical of class I and similar to class II DENV 
[47]. Numerous studies have shown that several regions are crucial for this fusion 
process including both membrane anchors, the FP, the transmembrane and membrane-
proximal regions [46, 48-50]. Many class I viral envelope proteins have been 
characterised including HIVgp41, HCV, SIVgp41, Ebola G, HTLV-1, RSV, HRSV, VSV-
G, SARS, and MoMuLV [46, 47, 51]. 
 
 1.7. Class II fusion and dengue virus E  
Class II fusion flaviviruses have one of the fastest and most efficient membrane fusion 
machineries of all enveloped viruses to date [20]. The dimeric E on the virus surface has 
the FP buried before binding. The E protein binds to one or more receptors and is 
internalised in the low-pH endosome. The acidic pH of the endosome causes 
dissociation of the E dimers, which allows DI and DII to flex relative to each other [23, 
29, 52]. Histidine 146 and 323 are critical pH sensors for this large-scale conformational 
change of E [53-55]. H323 is at the interface between DI and III and its protonation leads 
to the dissolution of domain interactions and exposure of the fusion peptide [56]. These 
histidines then form salt bridges with negatively charged residues in the post-fusion 
conformation [57]. Fusion does not occur until the late endosome/lysosome even though 
the pH is low enough in the early endosome. This is thought to be controlled by 
compartment-specific lipid composition [58]. The hinge region between DI and DII helps 
direct the FP toward the host membrane. This is facilitated by the presence of conserved 
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glycines in three of the four peptides connecting DI and DII [31, 59]. DII of E swings 
outward towards the host cell membrane at the DI-DII hydrophobic hinge region. This 
movement destroys the tight packing interactions on the outer surface of the virion, 
enabling the trimerisation of E and insertion of the FP into the outer leaflet of the host 
cell membrane. DIII shifts, folding back onto itself and in the process brings the viral 
membrane towards the FP and the host cell membrane [60]. As DIII moves toward DII, 
hemifusion of the lipid membrane occurs. This hairpin structure or hemifusion stalk in the 
“active fusion” form of trimeric E has the transmembrane and FP regions in close 
proximity in the fused membrane [21, 29, 61] (figures 9 and 10). The fusion pore flicks 
open and the virus then gains entry [62]. 
 
 1.8. Class III fusion  
There is a third class of fusion proteins, newly termed Class III, which have features of 
both Class I and Class II [63]. They contain a central trimeric coiled-coil, typical of Class 
I in their post-fusion state while three of their domains are predominately β-sheets, which 
is typical of Class II. VSV-G, Baculovirus gp64, and Epstein-Barr Virus gB are in this 
class, which also includes HSV-1 (a DNA virus) [64]. 
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Figure 9. Proposed fusion process of homotrimer E showing Class I (A) and Class II (B).  
[A] Class I fusion. (a). After binding to a receptor, or exposure to the low-pH conditions of the endosome, the 
fusion protein forms an extended conformation and the fusion peptide extends into the host membrane (b). 
Trimerisation of the protein (c) is followed by a conformational change of the fusion protein when the host 
cell and viral membranes fold towards each other (d). A restricted hemifusion stalk is formed, in which the 
outer leaflets of the lipid membranes mix (e), and finally the fusion peptide rearranges completely so that the 
fusion peptide and transmembrane domains are anti-parallel to each other, but in the same membrane (f).  
[B] Class II fusion. The dimeric E protein is on the virus surface with the fusion peptide (shown in green) 
buried in the dimer (a). E binds to a receptor and is internalised in the endosome. Under low-pH conditions, 
domain II swings outward towards the host cell membrane, presumably at the domain I–II hinge region (b). 
This conformational change allows the E proteins to rearrange laterally. The fusion peptide inserts itself into 
the outer leaflet of the host cell membrane, enabling trimerisation of the E protein (c). Domain III of the E 
protein folds back onto itself, and in the process brings the viral membrane towards the fusion peptide and 
host cell membrane (d). As domain III moves towards domain II, hemifusion of the lipid membranes occurs 
(e), and finally a trimer forms where the transmembrane regions and the fusion peptide are in close 
proximity [29]. 
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Figure 10. DENV pH-activated conformational change of E. E in monomeric form, from inactivated to 
“active fusion”. 
[A, B] The hinge between DI and DII allows rotation of DII from a horizontal to vertical position.  
[C, D] DIII shifts and rotates, directing DII to expose the FP region towards the host membrane for 
embedding. The hydrophobic residues of E2 pull the viral membrane in close proximity to the host 
membrane to allow for fusion pore formation and then re-orient into a hydrophobic trough formed by 
adjacent DII domains of the final trimeric E. 
 
!
A B 
C D 
 27 
 1.9. E stem and anchor region 
The stem or membrane-proximal external region (MPER) of E is composed of a 
membrane distal α-helix E1 (residues 398-420), a conserved region CS, and a 
membrane proximal α-helix E2 (426-448) [29, 34] (figure 11). There are two anchoring 
transmembrane regions, TM1 and TM2. 
Stiansy, et al. (1996) proposed that the E2 membrane proximal alpha helix between TM1 
and E1 of DIII is crucial for prME association and fusion [37, 65]. It is also thought to be 
fundamental in instigating curvature in the lipid bilayer, which is crucial for fission and 
fusion [66]. This may promote virus release by inducing membrane curvature at sites 
where virus budding occurs. The stem domain of E is rich in aromatic, hydrophobic 
residues and is highly conserved among flaviviruses [21] (figure 11). In DENV-2, E2 
contains four phenylalanine and one tyrosine residues (figure 12 and 13). E1 and E2 are 
both amphipathic with one face positively charged, which may help alleviate electrostatic 
repulsion between the membrane-facing surfaces of E (figure 14). During fusion, the 
charge interactions between the membrane, ectodomain and stem regions of E change, 
which leads to a rearrangement of E1 and E2 [31]. 
 
 
 
Figure 11. Diagram of the dengue virus E stem region. [Top] DI-DIII of DENV E with helices of 
membrane (yellow), transmembrane (middle blue), E1 and E2 (circled). [Bottom] Predicted E1 and E2 α-
helices are shown as cylinders (red). The “activation hinge” between DI and DII is underlined. 
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             Helix 1 (E1)                 Helix 2 (E2) 
  
TBE GSSIGRVFQKTKKGIERLTVIGEHAWDFGSAGGFLSSIGKAVHTVLGGAFNSIFGGVGFL 
YF GSSIGKLFTQTMKGVERLAVMGDTAWDFSSAGGFFTSVGKGIHTVFGSAFQGLFGGLNWI 
JE GSTLGKAFSTTLKGAQRLAALGDTAWDFGSIGGVFNSIGKAVHQVFGGAFRTLFGGMSWI 
DEN GSSIGKMFEATARGARRMAILGDTAWDFGSIGGVFTSVGKLIHQIFGTAYGVLFSGVSWT 
 
   
      400       410         420       430        440      450 
 
Figure 12.  Multiple sequence alignment of stem helical domains. The four major Flaviviruses are aligned, 
TBE (tick-borne encephalitis, YF (yellow fever), JE (Japanese encephalitis) and DEN (dengue). DEN refers 
to DENV-1 subtype. Helix 1 (E1) contains amino acids 398-420, helix 2 (E2) corresponds to residues 426-
448 [65]. 
 
 
 F422G S L GG * VF429T S I G K A L H Q VF440GG IY444GAAF448  
 
Figure 13. MPER α-helix E2 peptide sequence 422 to 488. In bold, green are nonpolar, hydrophobic 
residues. The remaining residues are all polar (either uncharged or basic). * proposed activation hinge 
 
 
 
Figure 14. Stem α-helices E1 and E2 location in the envelope glycoprotein. [Top] Diagram of the top-
down display of phenylalanine and tyrosine residues spiraling out of the α-E2 helix. The aromatic, 
hydrophobic side groups map to one side of the amphipathic helix. [Bottom] Stem α-helices E1 and E2 
location in the envelope glycoprotein. (Modified from P.R. Young) 
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The structural significance of this region has been previously investigated by the Young 
laboratory through mutation of the phe/tyr residues to non-conservative alanines as in 
figure 15. Three mutant constructs were created with either the first two (F422, F429), 
last two (Y444, F448) or all five phe/tyr residues mutated to alanines. Mutant prME 
constructs were transfected into mammalian cells and the expressed proteins prM and E 
were immunoprecipitated from 35S met-cys labeled cell lysates. The mutant heterodimers 
could be co-precipitated with monoclonal antibodies (MAb) against either the prM (2H2) 
or E (3H5) components, indicating that none of these aromatic residues were critical to 
prME heterodimerisation [67]. However, none of these mutants led to fusion indicating 
that they were crucial for the conformational changes leading to fusion peptide display. 
Theoretically, these substitutions were thought to have been enough to disrupt the E2 α-
helix configuration so that the conformational changes required for exposure of the FP 
could not occur [67]. These membrane-anchoring residues may be essential for 
maintenance of structural integrity, providing stability for DII to be move vertically, 
exposing the FP region and thus initiating fusion (figure 10). It is known that seven 
hydrophobic residues, one of which is F448, interact with the M protein for possible pre-
fusion stability in E’s heterodimeric state. These residues do not interact in homodimeric 
E [35]. F429 has been proven to be crucial in the formation of virus-like particles (VLPs), 
heterodimerisation and protein production. When mutated to proline in a pSFV replicon 
system, a lower rate of infectivity occurred, as well as low levels of protein expression 
and viral RNA production [68]. F422 has also been mutated to proline, resulting in 
decreased viral assembly and membrane binding. Peptides corresponding to this stem 
region (419 to 447) target a late-stage fusion intermediate resulting in loss of association 
with the lipid bilayer and inhibiting entry [69, 70]. There appears to be a specific 
interaction with DII, which inhibits the movement of DII in relation to DI, preventing the 
two membranes from pinching together. A stem-derived peptide appears to bind the 
post-fusion, trimeric form of E competing for binding to the stem, which blocks DII from 
“zipping” along the stem to create hemifusion of the membranes [71]. 
 
The Young laboratory has previously tested truncated versions of the stem and 
transmembrane domains of E and prM. The prM constructs generated included pr by 
itself, prM with no TM, prM with one TM domain only, and full-length prM (figure 16). 
Full-length E and prM expressed singly were located on the cell surface. Without prM as 
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a chaperone, E was not expected to migrate to the cell surface but this may be a fusion-
incompetent version [67]. PrM truncation constructs were co-expressed with full-length 
E. The only prM truncation to be expressed on the cell surface was prM with one TM 
segment. Stable heterodimer associations were formed with prM full-length and pr with 
at least one TM segment. PrM lacking a TM anchor was only partially successful in 
formation of the heterodimer. No fusion occurred with any of these truncated products, 
clarifying that the transmembrane and stem regions are crucial for heterodimerisation 
and consequently, fusion. 
 
  wild type  mutant 1  mutant 2  mutant 3 
 422 F   A   F   A 
 429 F   A   F   A 
 440 F   F   F   A 
 444 Y   Y   A   A 
 448 F   F   A   A 
 
Figure 15. Amino acid substitutions of the E2 α-helix. The four phenylalanine and one tyrosine residue 
substitutions were previously made by the Young laboratory (P.R. Young personal communication). 
 
 
 
 
Figure 16. PrM and E truncations of the stem region previously tested. Full-length pr and E, E and pr 
singly, pr with one TM segment deleted, both TM segments deleted and pr without the stem region. “Ss” 
represents signal sequence; the N-terminus cleavage site for C and prM. The parentheses corresponds to 
partial formation. 
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This study will further this research by mutating independently each phe or tyr to either 
non-conservative alanine or conservative, hydrophobic residues (tyrosine or 
phenylalanine), instead of group substitutions, (figure 17). The substitution with tyr or 
phe is expected to retain E anchored to the viral membrane so as not to disrupt the 
conformational change and bar fusion. 
     
  wild type mutant 1 mutant 2 mutant 3 mutant 4 mutant 5 
 422 F  A/Y  F  F  F  F   
 429 F  F  A/Y  F  F  F 
 440 F  F  F  A/Y  F  F 
 444 Y  Y  Y  Y  A/F  Y 
 448 F  F  F  F  F  A/Y 
 
Figure 17. Amino acid substitutions of the E2 α-helix. Shown are the four phenylalanine and one tyrosine 
residues that will be mutated. 
 
 1.10. Lentiviral pseudotyped particle expression system 
One of the problems associated with flavivirus fusion studies has been the quantification 
of fusion phenotypes for selected mutants of prM and E. Standard approaches for 
establishing quantitative fusion assays for dengue have been unsuccessful. An 
alternative approach is the use of pseudotyped retroviruses that could provide a 
measure of successful entry into target cells and therefore a measure of fusion. Lentiviral 
pseudotype vectors have been created for the expression of a variety of virus envelope 
proteins such as Hepatitis C [72, 73], Ebola [74], SIV-1 [75] and SARS [76]. Lentiviruses 
are primarily used in gene therapy although they have been proven useful in pantropic 
transduction [77, 78]. Lentiviral vector constructs have proven to be very productive in 
terms of transduction due to their ability to infect both replicating and non-replicating 
cells. A lentiviral expression system was developed to test fusion of MPER E2 mutants 
determined by wild-type prME results. 
The third generation, HIV-1 based system to be used in this project is noninfectious, as 
the replicative genes have been deleted and the minimal essential components have 
been separated onto independent plasmids (see figures 25-28, Appendix I). The four 
plasmids used in this system are: an “expression” construct containing gag and pol viral 
proteins, a “transfer” construct, which has the production and packaging elements, a 
“packaging” plasmid containing the viral envelope gene, and a fourth “reporter” vector 
containing luciferase or eGFP to analyze infectivity and transduction.  The commonly 
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used Vesicular Stomatitis Virus (VSV-G) envelope protein is recognised by a broad 
spectrum of cells and forms highly stable particles [79, 80]. The lentivirus is capable of 
transferring the reporter gene to infected cells but incapable of replicating (see figure 
15). 
 
 
 
Figure 18.  The lentiviral development pathway. Transfection of HEK 293Ts with the 3rd generation four 
plasmid system (pLL3.7, pRRE, pREV, NGC_prME) is followed by harvest of lentiviral supernatant. Cells are 
then transduced and analyzed to determine infectious units via FACS analysis [81]. 
!
 
 33 
1.12. Aim of Research Project 
The aim of this research project is to determine the structural significance of the 
membrane-proximal (MPER) E2 α-helix in Dengue’s E protein in pH-activated 
conformational change and its role in membrane fusion. Site-directed mutagenesis of the 
α-helix E2 will be carried out to determine the role of five individual residues in viral 
fusion (F422A/Y, F429A/Y, F440A/Y, Y444A/F and F448A/Y). A lentiviral expression 
system will be developed to assay fusion of E2 mutants. This expression system is a 
method of studying viral fusion of these mutants, which can be problematic. Structural 
characterisation of the mutants will be investigated by cell surface expression including 
co-immunoprecipitation to confirm protein expression and prME heterodimerisation. 
Immunofluorescence will be used to view protein expression, co-localisation of prM and 
E and cell surface trafficking. Fluorescent activated cell sorting and flow cytometry will be 
used to determine cell surface expression. The elucidation of host-viral fusion of wild-
type and mutant prME viral particles ideally would be studied by alternative pathways 
such as a fusion assay. 
 
1.12.1. Specific Aims 
1. Site-directed mutagenesis of the membrane-proximal (MPER) α-helical E2 domain of 
DENV E to obtain full-length prM and E mutant plasmids that will be used in all 
subsequent research (Chapter 3).  
 
2. Develop a lentiviral expression system to assay fusion of these E2 mutants (Chapter 
4). 
 
3. Investigate and characterise the structure of prM and E mutants by cell surface 
expression and host-viral fusion in a mammalian cell line by: 
a. FACS analysis to detect and quantify cell surface expression. 
b. Protein expression confirmed by SDS-PAGE and Western immunoblot. 
c. Immunofluorescence to confirm in-cell prM and E expression, co-
localisation, and cell surface trafficking (Chapter 5). 
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4. Investigate the structure of prM and E mutants in a pSFV-based vector. Characterise 
these mutants for cell surface expression and host-viral fusion in an insect cell line by: 
a. FACS analysis to detect and quantify cell surface expression. 
b. Protein expression confirmed by SDS-PAGE and Western immunoblot. 
c. Immunofluorescence to confirm in-cell prM and E expression, co-
localisation, and cell surface trafficking (Chapter 6). 
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CHAPTER 2 
MATERIALS AND METHODS 
2.1. Vectors 
2.1.1. pCI_NGCprME_opt_neo plasmid 
 
 
 
 
Figure 19.  Plasmid map of pCI_NGCprME_opt_neo (New Guinea DENV 2, optimized, neomyocin). The 
vector contains the prME genes (E2 domain noted), NeoR and ampR genes. 
 
Geneart designed pCI_NGCprME_opt_neo. The vector has a chimeric intron after the 
CMV promoter/enhancer to promote high levels of gene expression and a SV40 late 
polyadenylation signal to enhance RNA stability and translation. It has an ampicillin 
resistance gene as well as an additional gene for neomycin phosphotransferase, which 
confers resistance to the antibiotic G-418. A LacZ gene facilitates blue-white screening.  
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2.1.2. pSFV plasmids 
 
 
 
 
Figure 20.  Plasmid map of pSFVprME. Displayed are the prME genes inserted into wild-type pSFV 
plasmid. 
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The pSFV replicon (Semliki Forest Virus) was acquired from Invitrogen. It is a full cDNA 
clone of SFV, with the genes encoding the structural proteins removed. The non-
structural proteins, 26S subgenomic RNA promoter, 5’ and 3’ untranslated elements 
required for replication remain, and the vector system can be used to express genes in 
both mammalian and insect cells. The region between restriction sites Sph I and BamH I 
was replaced with a linker designed as follows: Sph I – BamH I – Xho I – AAAACCCC – 
Not I –BamH I. The original BamH I site was lost. This allowed for digestion with Xho I 
and Not I to insert prME, which was named the pSFVprME “cassette” vector. This was 
then digested with BamH I and Spe I and ligated with a digested full-length pSFV to 
make a vector that is full-length pSFV with prME cloned in. 
The plasmid is linearised with Spe I and transcribed in vitro to produce RNA transcripts 
for transfection into C6/36 cells. Primers were designed to check insertion of prME and 
correct cloning direction as follows: 
 
To sequence 5’ end of prME in pSFVprME “cassette” vector: 
PDP R1 (Rev)     GTACTGCACGCGGATCACGAT 
prME_Seq_Rev_5'end    TGTCCTCGCACAGCTCG 
 
To sequence 3’ end of prME and check mutations in pSFVprME “cassette” vector: 
PDP R1 (Rev)     GTACTGCACGCGGATCACGAT 
prME_SeqMut_Fwd_3'end   TGCAGTACGAGGGCGAC 
 
To sequence pSFV to check prME insertion and correct orientation: 
PDP R1 (Rev)     GTACTGCACGCGGATCACGAT 
prME_InsCheck_Fwd    TCGTGTGTGTAAGCACTCTATG 
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2.3.1. Lentiviral plasmids: pRRE, pREV, pLL3.7, and pMD.G 
 
 
 
 
 39 
 
 
 
 
 
Figure 21.  Lentiviral plasmids pLL3.7 (luc+), pRRE, pREV, and pMD2.G (VSV-G). 
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Lentiviral vector constructs have proven to be very productive in terms of transduction 
due to their ability to infect both replicating and non-replicating cells. A four-plasmid 
vector system is used in the third generation lentiviral expression system (figure 21). The 
accessory proteins such as tat, vrf, vpr and nef are deleted from the original plasmid. 
Also, the env gene is replaced with a VSV-G (Vesicular Stomatitis Virus Envelope 
Protein) and is placed on a third helper plasmid. By splitting the vector system into four 
plasmids, the number of recombination events required to form a complete replicative 
competent virus increases yet this system is safer to use. The four-plasmid system 
consists of pRRE (gag, pol), pREV (production and packaging), pLL3.7 (GFP fluorescent 
protein), and pMD.G (VSV-G envelope protein). pMD.G can also be replaced with 
pCI_NGCprME_opt_neo to use prME envelope protein in lieu of VSV-G. Dr. Nigel 
MacMillan generously provided the plasmids. 
 
2.3.1.1. pLL3.7, pGL-3, and pLL3.7_luc+ 
Luciferase was cloned into pLL3.7 in lieu of GFP. This was to test the expression system 
via a luciferase assay instead of FACS. pLL3.7 vector was digested with Nhe I and EcoR 
I, which results in a 6907 bp vector and a 742 bp insert containing eGFP. pGL-3 
(IMB/Invitrogen) was digested with Xba I and Bgl II resulting in a 1706 bp insert 
containing the luciferase gene. These plasmids were digested overnight with Klenow 
fragment in the presence of dNTPs and the correct sized bands (6907 bp for pLL3.7 and 
1706 bp for pGL-3) were gel extracted. The two bands were then ligated together to form 
pLL3.7_luc+. 
 
Figure 22.   Plasmid maps for cloning of the luciferase gene. pGL-3 (right) and pLL3.7 (left). pGL-3 was cut 
with Bgl II and Xba I and pLL3.7 was cut with Nhe I and EcoR I. The luc+ region from pGL-3 was ligated into 
the GFP region in pLL3.7 via blunt-end cloning. The luciferase assay can then be used in lieu of FACS. 
 41 
 2.2.  Prokaryotic cell culture 
     2.2.1.    Culture 
Escherichia coli strains used for routine culture work were either XL-10 Gold or H5-α 
cells. Chemically competent cells were routinely made and stored at –80ºC until 
required. Bacteria were cultured in Luria-Broth (LB; 10 g/L tryptone or peptone, 5 g/L 
sodium chloride, 10 g/L yeast extract) with 100 µg/ml ampicillin. Agar plates were 
prepared by addition of 16 g/L bactoagar to LB media prior to autoclaving, and 100 µg/ml 
ampicillin prior to plating. Bacterial plates were grown at 37ºC for 16-24 hours. 
 
2.2.2. Transformation 
Competent cells were thawed on ice, and 1 µl of plasmid DNA was added to a 100 µl 
aliquot of cells. The mixture was flicked gently to mix, and incubated for 15 minutes on 
ice before being heat shocked at 42 ºC for 2 minutes. After recovering on ice for a further 
3 minutes 900 µl LB media at room temperature (RT) was added and cells incubated at 
37 ºC with shaking for 30 minutes. Approximately 100 µl cells was plated and grown 
overnight. Cells were plated on ampicillin agar plates and grown overnight. 
 
2.2.3. DNA purification 
Miniprep cultures of 3-5 ml were inoculated with a single colony from a fresh ampicillin 
plate and grown overnight at 37 °C at 200 rpm in an environmental shaker. DNA was 
extracted using a Invitrogen’s Purelink Plasmid Miniprep kit according to the 
manufacturer’s instructions. Maxiprep cultures of 50-100 ml were used to grow up large 
amounts of DNA for transfection experiments. Maxipreps were inoculated from a 
miniprep grown for 8 hours. Maxiprep cultures were grown for 16 hr at 37 °C at 200 rpm 
in an environmental shaker and purified using Purelink Plasmid Maxiprep kits 
(Invitrogen) to make sure endonucleases were removed. 
 
2.3. DNA Engineering  
2.3.1. Restriction endonuclease digests 
Plasmid DNA was digested using approximately 1 µg of enzyme to 1 µg DNA. 
Restriction reactions were carried out in the appropriate buffers supplied with the 
enzymes (New England Biolabs) and bovine serum albumin (BSA) where appropriate. 
All digests were carried out at the recommended temperature for 2 hours to overnight. 
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2.3.2. Ligation 
Ligations were performed using 100 ng of vector and a vector to insert molar ratio 
ranging from 1:1 for blunt end ligations to 1:3 for cohesive end ligations, although a 
range of ratios were sometimes used to optimise cloning. Ligations were performed 
using Quick T4 DNA Ligase Kit (NEB, New England Biolabs) using the recommended 
amount of buffer and ligase. Reactions were incubated for 10 minutes at RT and 
transformed immediately. 
 
2.3.3. Gel electrophoresis 
Agarose gels were 1 % agarose in 50 or 100 ml TAE buffer (0.014 M Tris-acetate and 
0.001 M EDTA pH 8.0) and contained 2 or 4 µl ethidium bromide. Separation was 
performed by electrophoresis in submerged horizontal trays with TAE buffer at 100 
Volts for one hr. Prior to loading, the DNA samples were mixed with 2 µl loading buffer 
(10mM Tris-HCl, 1 mM EDTA, 3 % Ficoll, 0.5 % bromophenol blue, 0.5 % xylene 
cyanol). Generuler 1kB Mix DNA marker was used (Fermentas). DNA was visualised 
using an ultraviolet transilluminator and photographed. !
2.3.4. Gel Extraction 
DNA fragments were extracted from agarose gel blocks using Purelink Quick Gel 
Extraction kit (Invitrogen) or Zymoclean Gel DNA Recovery kit (Zymo) according to the 
manufacturer’s instructions. 
 
2.3.5. Site Directed mutagenesis 
PCR mutagenesis was performed with complimentary oligonucleotides in a touchdown, 
two-step PCR with 1 Unit of Phusion polymerase (Finnzyme), using Buffer GC, 0.5 µM 
primers, 50 ng NGC_prME_opt_neo template, 0.5 mM dNTPs, 1.5 mM MgCl2 and 5% 
DMSO in a 50 µl reaction. Oligonucleotides were ordered through Sigma-Genosys and 
stored at 100 µM concentrations in 1X TE. The following cycling conditions were used in 
an ABI GeneAmp PCR System 2400 or Eppendorf Thermocycler Personal: 98ºC for 1 
minute, 2 cycles of 98ºC for 10 seconds, 60ºC for 30 seconds, and 72ºC for 10 minutes 
after which, the primer solutions are added to the reactions. The second stage PCR 
begins with 98ºC for 2 minutes, followed by 30 cycles of 98ºC for 20 seconds and 72ºC 
for 6 minutes with a final extension of 72ºC for 10 minutes and a 4ºC hold. PCR 
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amplicon was purified with PureLink PCR Purification kit (Invitrogen), treated with Dpn I 
(New England Biolabs), purified again and transformed as above. Primers designed for 
site-directed mutagenesis of the α-E2 helix are listed in table 1. 
 
Mut. Forward Primer Reverse Primer 
F440A 5’-CACCAGGTGGCCGGAGCCATCTACGGA-3’ 5’-GATGGCTCCGGCCACCTGGTGCAG-3’ 
F440Y 5’- CTGCACCAGGTGTACGGAGCCATCTACGGA-3’ 5’-TGGCTCCGTACACCTGGTGCAGGGCCTT-3’ 
F448A 5’-GAGCCGCCGCCTCCGGCGTGT-3’ 5’-GACACGCCGGAGGCGGCGG-3’ 
F448Y 5’-GCCTACTCCGGCGTGTCCTGGACC-3’ 5’-CGGAGTAGGCGGCTCCGTAGATGGCTC-3’ 
F422A 5’-GCAGCCTGGGCGGCGTGGCCACCTCCATCGG-
3’ 
5’-
CCGATGGAGGTGGCCACGCCGCCCAGGCTGC-3’ 
F422Y 5’-GCAGCTGGGCGGCGTGTACACCTCCATCGG-3’ 5’-CCGATGGAGGTGTACACGCCGCCCAGGCTGC-
3’ 
F429A 5’-GACACCGCCTGGGACGCCGGCAGCCTGGGC-3’ 5’-GCCCAGGCTGCCGGCGTCCCAGGCGGTGTC-
3’ 
F429Y 5’-GACACCGCCTGGGACTACGGCAGCCTGGGC-3’ 5’-GCCCAGGCTGCCGTAGTCCCAGGCGGTGTC-
3’  
Y444A 5’-
GTGTTCGGAGCCATCGCCGGAGCCGCCTTCTCCG-
3’ 
5’-
CGGAGAAGGCGGCTCCGGCGATGGCTCCGAAC
AC-3’ 
Y444F 5’-
GTGTTCGGAGCCATCTTCGGAGCCGCCTTCTCCG-
3’ 
5’-
CGGAGAAGGCGGCTCCGAAGATGGCTCCGAACA
C-3’ 
 
Table 1.  pCI_NGCprME_opt_neo oligonucleotides. These primers were used for site-directed 
mutagenesis of the α-E2 helix. Residues F440A/Y, F448A/Y, Y444A/F, F429A/Y, F422A/Y were mutated. 
The mutated codon is in italics. 
 
2.3.6. Colony diagnostic PCR 
Colony screening of mutants to confirm insertion of prME or linkers was performed with 1 
colony diluted in 100 µl of water, of which, 1 µl was added to each PCR reaction. Colony 
diagnostic PCR was performed with 0.05 U/µl Taq polymerase (NEB), using 25 mM Tris 
pH 8.3, 50 mM KCl, 2.5 mM MgCl2 and 20 µM primers. Oligonucleotides were ordered 
through Sigma-Genosys and stored at 100 µM concentrations in 1X TE. 
 The following cycling conditions were used in an ABI GeneAmp PCR System 2400 or 
Eppendorf Thermocycler Personal: 95ºC for 4 min, 30 cycles of 95ºC for 15 sec, 50ºC for 
15 sec, 72ºC for 60 sec, a final extension of 72ºC for 5 min and a 4ºC hold. Non-purified 
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amplicon was digested with appropriate diagnostic restriction endonucleases and run 
against vector controls. 
 
2.3.7. Sequencing 
Plasmid DNA and sequencing oligonucleotides were submitted to the Australian 
Genomic Research Facility (AGRF). Sequences were analysed using Vector NTI version 
10 (Invitrogen). 
 
2.4.    RNA Engineering 
2.4.1. Plasmid precipitation and linearisation 
RNA was precipitated with 1/10th volume of 3M Na acetate and three volumes of 100% 
EtOH. Samples were incubated on ice for 20 minutes or overnight at -20°C. Tubes were 
then centrifuged at top speed for 15-30 min at RT. Pellets were washed with 1 ml 70% 
EtOH then chilled in an ice bath for 10 minutes. Tubes were centrifuged at top speed for 
5 minutes. EtOH was carefully removed and RNA was re-suspended in TE. RNA was 
linearised with Spe I in buffer # for 2 hours at 37°C. 
 
2.4.2. RNA Transcription 
In vitro transcription was performed in a 20 µl reaction containing 1 mg linearised cDNA, 
80 mM Hepes – KOH (pH 7.5), 32 mM MgCl2, 2 mM spermidine, 40 mM dithio- threitol, 
5 mM each of GTP, CTP and UTP, 1.5 mM ATP, 3.5 mM m7G(57)ppp(57)A cap analog 
(New England Biolabs) and 20–40 U SP6 RNA polymerase (Gibco BRL) or 2 ml SP6 
RNA polymerase – pyrophosphatase mix (SP6 Ribomax kit, Promega). Following 
incubation at 40°C for four to six hours, the reaction mixture was either used directly for 
transfection or stored overnight. 
 
2.4.3. RNA Transfection 
RNA was transfected in C6/36 cells in 96-well plates. 0.4 µl of RNA and 0.8 µl of 
lipofectamine-2000 (Invitrogen) were added into 25 µl of SF media. After four to six 
hours, 50 µl of media was added to wells. At sixteen hours, media was taken off and 
cells were fixed. If a pH drop was tested, media was taken off and low pH media was 
added (5.5, 6 or 7.5 HCl adjusted pH, RPMI Hepes free, 15 mM MES). Samples were 
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incubated for three hours at 40°C. Cells were then fixed and stained with Hoechst and 
appropriate antibodies. 
  
2.5. Eukaryotic cell culture 
2.5.1. Maintenance of mammalian cell lines 
Cell lines used were Vero (African Green Monkey Kidney), HEK 293T (Human 
Embryonic Kidney), PS-EK (Porcine Stable-Equine Kidney) and C6/36 (Aedes 
Albopictus), all of which were provided from Young laboratory stocks. Media was 
removed from the flasks and cells were washed with 1X PBS (Phosphate buffered saline 
solution). Trypsin was added (2 ml for a T75 flask) and incubated at 37º C for five (Vero) 
or seven minutes for PS-EK cells. Flask was tapped gently to loosen cells and media 
added at a 1:4 trypsin:media ratio. Cells were then split (e.g. 1:10 split uses 1 ml of cells 
and 9 ml of fresh media into a new T75 flask). Generally, Opti-mem I media was used 
with 10% fetal calf serum (FCS) for Vero cells, DMEM media + 10% FCS was used for 
HEK 293T and PS-EK cells. Flasks were incubated overnight at 37ºC and checked for 
confluency daily. 
 
2.5.2. Cell line rescue and storage 
Cell stocks were partially defrosted and 20 ml of appropriate media was used to wash 
them. Cells were centrifuged for 5 minutes at 120 x g, 4ºC. Supernatant was poured off 
and cells were re-suspended in 10 ml growth media. Cell solution was added to a T25 
flask and incubated overnight. After confluent, cells were split into a T75 or T175 flask. To 
store cells, media was removed from the flasks and cells were rinsed 2x with 1X PBS.  
Flasks were trypsinised as above. Cells were resuspended in 10 ml fresh media and 
moved to a 25 ml Falcon tube. Cells were centrifuged for five minutes at 200 x g, 4ºC. 
Supernatant was poured off and cells were resuspended in ice-cold freezing media (40% 
Media, 10% DMSO, 50% FCS), (i.e. three ml for one T75 flask). Cells were stored at -
80ºC overnight in an EtOH bath and then transferred to a liquid nitrogen dewer the 
following day. 
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2.5.3. Transfection 
PS-EK, HEK 293T, or Vero cells were seeded (2 x 105 cells/ml) onto sterile coverslips in 
24-well Falcon plates and grown overnight at 37ºC + 5% CO2. 1 µg of DNA was added 
to 3 µl of Lipofectamine-2000 (Invitrogen). 50 µl of serum-free Opti-Mem I was added to 
a Falcon tissue culture tube with DNA or Lipofectamine. Solutions were incubated for five 
minutes and then added together and incubated a further twenty minutes. Mixtures were 
added to cells drop-wise and incubated for four to six hours at 37ºC + 5% CO2. Media 
was then changed and cells were incubated for another 24 hours. Cells were then 
washed 1x in 1X PBS and fixed in 4% PFA (in PBS) for fifteen minutes at 4°C. If cells 
were permeabilised, PFA was discarded and 4% PFA + 0.2% TX100 added. Plates were 
incubated for fifteen minutes at 4°C and cells were washed with 1X PBS. 
 
2.5.4. Infection 
Cells were seeded (2 x 105 cells/ml) in six-well plates with 1.5 – 2 ml media and grown 
overnight at 37ºC + 5% CO2. Media was removed and 1 ml serum-free (SF) media was 
added with virus neat and in dilutions (i.e. 5-fold) with a starting m.o.i. = 0.1 to 10 
generally used. Cells were incubated for two hours and 3 ml complete media was added 
and incubated overnight. Cells were then washed and fixed as above. 
 
2.5.5. Virus stock production 
C6/36 (Aedes albopictus) cells were used to generate DENV-2 viral stocks. Sealed T175 
flasks with 25 ml RPMI media (15 mM Hepes pH 7.3 and saturated sodium 
Hydroxide) were incubated at 28°C. Cells were cultured to approximately 80% 
confluency and virus stock added at 1:10 dilution in SF media. Flasks were incubated at 
28°C until cytophatic effects (CPE) such as synctial formation and irregular growth were 
observed. Supernatant was removed from the cells and clarified by centrifugation at 500 
rpm for 5 minutes and stored at -80°C in 1 ml aliquots. 
 
2.5.5.1.     Plaque Assay 
Viral stock titre was determined by plaque assay. Vero cells were seeded in 96-well 
plates at 200 µl, 1 x 105 cells/ml and cells were grown overnight. Cells were then washed 
with 1X PBS and virus stocks were diluted in series from 10-2 to 10-8 in SF media. 
Dilutions were transferred to the cells and incubated for two hours at 37C. Cells were 
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then overlayed with 1.5% carboxymethylcellulose (CMC) in Medium 199 (Life 
Technologies) with 2.5% FCS and incubated for four days at 37ºC. On the fourth day, 
the overlay was removed and cells were washed with 1X PBS. Cells were fixed in 200 µl 
ice cold 80% acetone in PBS for twenty minutes at -20°C and the plate was dried 
overnight. The plates were developed with 200 µl 9% MeOH/10%H2O2 for twenty 
minutes. Cells were then washed with PBS/0.1% BSA on a shaker. The plate was then 
blocked with 200 µl PBS/0.1% BSA. A 1:200 dilution (50 µl) of rabbit anti-NS1 polyclonal 
serum in PBS/0.1 % BSA was added and incubated for one hour at RT. The cells were 
then washed twice with 1X PBS/0.1 % BSA. A 1:500 dilution of secondary antibody, goat 
anti-rabbit peroxidase-conjugated) was added and cells were incubated for one hour at 
RT. The plate was washed with 1X PBS/0.1 % BSA. Plaques were visualised with 100 µl 
SIGMAFAST™DAB by dissolving 2 DAB tablets and 2 H202 tablets in 10 ml dH20. The 
plate was incubated in the dark and when plaques were seen, the reaction was stopped 
by washing with dH20. Plates were then scanned and plaques were counted. Viral titre 
was estimated. 
 
2.6. Lentiviral expression system 
2.6.1. Transfection  
HEK 293Ts cells were seeded in twelve T75 flasks in DMEM + 10% FCS at low passage 
number (>15). Four plasmids were transiently co-transfected with 270 µg of pLL3.7 
(eGFP), 176 µg of pRRE, 68 µg of pREV and 95 µg of pMD.G (VSV-G) (figure 21). 
Plasmids were mixed with 13.5 ml of 0.25M CaCl2 and 13.5 ml 2X BBS solution. After a 
15 minute incubation, the transfection mix was gently added to flasks drop-wise and 
incubated at 37°C overnight. The following day, cells were tested for visible GFP marker 
under fluorescent microscopy. Media was removed and 15 ml DMEM + 2% FCS was 
added to the flasks, which were incubated overnight at 37°C. Supernatant was pooled 
the following day for a total of 180 ml. Fresh DMEM + 2% FCS was added to the flasks, 
which were re-incubated overnight. A second pool was obtained the following day and 
added to the primary pool. Supernatant was filtered through a 0.45-µm filter. This 
supernatant should have had a viral titer of ~106 viral particles/ml. When a concentration 
step was performed, supernatant was centrifuged in Vivaspin columns (100,000 mwco) 
at 4°C, 3000 rpm. Ultracentrifugation was also performed where supernatant was 
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centrifuged at 70,000 x g and 20°C for 15-30 minutes. Supernatant was stored at 4°C if 
used immediately or at -20°C for less than a month or -80°C for periods over a month in 
20 µl aliquots. 
 
2.6.2. Transduction 
HEK 293T cells were then seeded in 24 well plates (1 x 105 cells/500 µl) in PBS + 0.02% 
EDTA. A ten-fold serial dilution of lentiviral supernatant was prepared from undiluted to 
50 µl diluted to 10-6 in 1X PBS. Viral dilutions were added to the cells, mixed and 
incubated at 37°C overnight. GFP fluorescence was visible 24 hours after transduction. 
Cells were further incubated for 24 hours, then washed twice with 1X PBS and re-
suspended in 500 µl 1X PBS + 0.02% EDTA by vigorously pipetting up and down. 
Percentage of viable cells and fluorescent cells was determined by FACS analysis and a 
mock transduction was subtracted from sample numbers. The biological titer (BT = 
TU/ml) was calculated according to the formula: TU/µl = P X N / 100 x V) x 1/DF where P 
= % GFP+ cells, N = number of cells at time of transfection = 105, V = volume of dilution 
added to each well = 20 µl and DF = dilution factor = 1 (undiluted), 10-1 diluted 1/10, 10-2 
dilution 1/100, and so on. 
 
2.6.3. Luciferase assay 
 2.6.3.1.    Transfection with control plasmids 
Control plasmids pGL-3b (“basic”, negative control), pCI (empty, negative control), 
pGL3c (positive “control”, which contains Photinus pyralis firefly gene), and the 
engineered pLL3.7_luc+ were tested in a luciferase assay. Vero cells were seeded at 2.5 
x 105 cells/100 µl in a 96-well plate and grown overnight. DNA was transfected at 0.2 µg 
with 0.5 µl of Lipofectamine-2000 in serum and phenol-red free media. Solutions were 
incubated for 5 minutes at room temperature, mixed and incubated again for twenty 
minutes. Solutions were added drop-wise to cells and incubated at 37°C for five hours. 
Solutions were taken off and 100 µl of serum and phenol-red free media was added. 
After overnight incubation, 100 µl of Bright Glo Luciferase substrate (Promega) was 
added to wells and immediately assayed on a luminometer (Althos Lucy).  
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 2.6.3.2.    Transfection to generate pseudotyped particles 
The lentiviral plasmids were used to generate pseudotyped particles with pLL3.7_luc+ 
instead of the GFP version. HEK 293T cells were transiently co-infected with the four 
lentiviral expression constructs pRRE (packaging), pREV (Rev-expression), pMD.G 
(VSV-G envelope), and the luciferase expressing pLL3.7 luc+ reporter plasmid. Cells 
were seeded in 6-well plates at 2.5 x 105 cells/2 ml and transfected the following morning 
in the presence of Hepes-buffered H20, 0.5M CaCl2, and 2X BES buffer. Concentrations 
of plasmids were as follows: 2.5 µg pMD.G, 3.75 µg pRRE, 3.75 µg pREV, and 10 µg 
pLL3.7_luc+ per plate or per 12 ml. Two other controls were prepared with pGL-3b 
(basic, no luciferase activity) or pGL-3c (control, positive luciferase activity) used in lieu 
of pLL3.7_luc+. Media was changed one hour prior to transfection and 16 hours post-
transfection. Supernatant was collected two days post-transfection and then again on 
day three, pooled, centrifuged and filtered through a 0.45 µm Millipore cartridge. 
For infection, Vero cells were seeded at 2.5 x 105 cells/100 µl in a 96-well plate and 
grown overnight. Lentiviral supernatant was added in serum and phenol-red free media 
at 2.5-fold dilutions from 50 µl to 0 and incubated at 37°C for two hours, after which 
infection solutions were taken off and 100 µl of serum and phenol-red free media was 
added. After overnight incubation, 100 µl of Bright Glo Luciferase substrate (Promega) 
was added to wells and immediately assayed on a luminometer (Althos Lucy).  
 
2.6.4. Cell viability assay 
To confirm lentiviral particles were not cytotoxic to cells, a cell viability assay was carried 
out with luciferase lentivirus stocks (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide, a yellow tetrazole (MTT)). A 96-well plate was seeded with HEK 293T cells (2.5 
x 105 cells/100 µl) and incubated overnight. The following day, cells were washed with 
1X PBS and 100 µl of SF media was added. A serial dilution of lentivirus stock was 
prepared in SF media. Dilutions were added to the cells and incubated for the stated 
time. After incubation, media was replaced with the addition of 10 µl MTT (5 mg/ml in 
PBS, Sigma). Cells were incubated for 3 hours at 37°C in the dark. The dye was 
solubilized with 100 µl acidic isopropanol (0.04 M hydrocholoric acid in isopropanol) and 
the plate was incubated on an orbital shaker in the dark for four hours. The absorbance 
was read at 550 nm on a spectrofluorometer. 
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2.7. Protein Expression 
2.7.1. Cell Lysate preparation 
The day following transfection, six-well plates were incubated on ice and supernatants 
were removed. The supernatants were spun at 4500 rpm, 4°C for ten minutes and then 
frozen at -20°C. Plates were washed with 1 ml 1X cold PBS and cells were lysed with 
200-500 µl cold 1X RIPA buffer (50 mM Tris-1 mM EDTA, 150 mM NaCl, 1% Triton-X, 
1% Na-deoxycholate, and 0.1% SDS) + protease inhibitor cocktail (Roche). Cells were 
incubated on ice for five minutes and plate bottoms were scraped. Lysed cells were 
transferred to 1.5 ml eppendorf tubes and sheared with a 26cc needle and syringe. Cells 
were spun at 14,000 rpm, 4°C for ten minutes and supernatants were stored at -20°C in 
25 µl aliquots. Alternatively, total cell lysates were prepared by solubilising cells in a 
sodium dodecyl-sulfate (SDS) hot lysis buffer. After PBS wash, 100 µl 2% SDS/66 mM 
Tris pH 7.4 (heated to near boiling) was added to the cells. Plate bottoms were then 
scraped and transferred to 1.5 ml eppendorf tubes. Lysates were sheared with a 26cc 
needle and syringe and boiled for two to three minutes. Cells were then centrifuged at 
14,000 rpm for ten minutes at 4°C and stored as above.  
 
2.7.2. SDS Polyacrylamide gel electrophoresis 
To separate protein by electrophoresis, 12% resolving/4% stacking polyacrylamide gels 
were used. 5X SDS-PAGE sample buffer (with or without 1 µl 1M DTT) was added to the 
samples, which were then boiled for five minutes. Samples were loaded with 7 µl BioRad 
Dual Stain Precision Plus Protein marker and gels run at 110V for ten minutes until 
samples were at the end of the stacking gel and then run at 200V for 40-42 minutes.  
 
2.7.3. Western transfer and Immunoblotting 
Gels were removed from their cassettes and equilibrated in 1X Transfer buffer (25 mM 
Tris-HCl pH 8.3, 192 mM glycine, 20% (v:v) MeOH) along with blotting paper, 
nitrocellulose membrane and sponges for two to three minutes. Transfer cassettes were 
then assembled with four papers on either side of gels. Gels were transferred to 
nitrocellulose membranes under submerged conditions at 100V for one hour. Cassettes 
were disassembled and the membrane was placed in blocking solution (5% skim-milk 
powder (MP) in PBS or 1% BSA) overnight at 4°C or for one hour at RT. Membranes 
were blocked in 5% MP, 1X PBS for one hour at 4°C. Membranes were then incubated 
 51 
with primary antibody at 37°C for one hour (or overnight at 4°C) at 1:1000 dilution (6 
mg/ml stock) in 3 ml in a sealed bag, which was gently shaken every fifteen minutes. 
Membranes were washed with 3X PBS + 0.1% Tween for five to ten minutes and 
membranes were incubated for one hour at RT with conjugated secondary antibody (IR 
800) at 1:10,000 in 5 ml. Membranes were then washed 3X PBS + 0.1% Tween for five 
to ten minutes and dried for five minutes under the biohazard hood. Membranes were 
then scanned on a Bio-RAD GS™-700 densitometer. 
 
2.7.4. Immunofluorescence: Antibodies and Molecular Probes 
After cells were fixed (4% paraformaldehyde (PFA) for 10 minutes at 4ºC) or fixed and 
permeabilised (4% PFA + 0.2% Triton-X for 10 minutes at 4ºC), cells were washed (1 ml 
PBS, 3X five minutes), air dried and stored at 4ºC. Cells were then stained with 30 µl of 
diluted DENV anti-E mAb 3H5 or 4G2 in PBS + 0.1% BSA. A 1:200 to 1:400 dilution was 
generally used. After incubation for one hour in the dark, coverslips were washed with 1 
ml PBS, 3X for five minutes. Cells were dually labeled with 30 µl, 1:400 dilution of 
0.5mg/ml Alexa-Flour 488 (Molecular Probes goat anti-mouse IgG conjugate) in PBS + 
0.1% BSA and then washed as before. Coverslips were briefly dried on top of filter paper 
and mounted to microscope slides with Vectashield™ (Vector Labs). Cells were also 
stained with 30 µl, 1:10,000 dilution of Hoechst or propidium iodide where indicated. 
Dye-tracking studies were carried out with organelle dyes CMAC, CM DiI, WGA (Wheat 
Germ Agglutinin), and ER-Tracker, (Molecular Probes) at various concentrations. Cells 
were viewed with the Zeiss LSM 510 Meta Confocal Microscope, captured at 40-160X 
magnification with the provided Zeiss software. 
 
2.7.5. Immunofluorescence: Flow Cytometry 
Plate wells were washed with 1 ml 1X PBS and incubated with 200 µl Trypsin for 5 
minutes at 37ºC.  Cells were gently removed from the wells with 1 ml media and 
transferred to 15 ml Falcon tubes. Cells were then centrifuged at 300 x g for 5 minutes 
and washed 3X with 1 ml 1X PBS. Cells were fixed (1% paraformaldehyde (PFA) for 10 
minutes at 4ºC), centrifuged and cell pellets were re-suspended in 500 µl 0.5% PFA. 
FACS data was acquired within three days, usually the following day (FACS BD LSRII 
and BD FACSDiva software).  
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CHAPTER 3 
RESULTS: DESIGN of pCIprME_opt_neo MUTANT PLASMIDS 
3.1. Introduction 
PCR mutagenesis was performed in a touchdown, two-stage PCR with Phusion 
polymerase and NGC_prME_opt_neo template [82]. All ten MPER E2 mutants were 
produced with single-point mutation oligonucleotides. The first PCR stage cycling 
conditions were as follows: 98ºC for one minute, two cycles of 98ºC for ten seconds, 
60ºC for thirty seconds, and 72ºC for ten minutes after which, the primer solutions are 
added to the reactions. This decreases primer-dimer formation and thus increases 
affinity for the template. The second stage PCR begins with a 98ºC melt for two minutes, 
followed by thirty cycles of 98ºC for twenty seconds and 72ºC for six minutes with a final 
extension of 72ºC for ten minutes and a 4ºC hold. With Phusion polymerase, it is 
possible to mutate one amino acid while maintaining a high degree of fidelity throughout 
the 7.4 kB plasmid. Following cloning, the mutated plasmids were sequenced for the full 
7400 base pairs. Samples were submitted to the Australian Genomic Research Facility 
(AGRF) and sequences were analysed using Vector NTI version 10 (Invitrogen). 
 
3.2. Results 
The touchdown, two-stage PCR with Phusion polymerase was optimised to increase 
specific amplicon and reduce non-specific product. To optimise this long PCR, additional 
enzyme was added halfway through the reaction to prevent enzyme-deficiency, DMSO 
was increased to 5%, MgCl2 was increased to 3.0 mM, annealing temperatures were 
lowered from 65 to 60ºC and the master mix buffer was changed from Buffer HF (high 
fidelity) to GC (high GC content in template). Although there was a large amount of non-
specific product, the amplicon was sufficiently identifiable to continue with cloning 
(Mutants F422A/Y and F448Y/A shown in figure 23). 
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Figure 23.              Two stage PCR amplicon with Phusion. Pooled amplicon (arrow) F440A, F440Y, F448A, 
and F448Y, Lanes 6 and 7 are no primer controls. This amplicon was subsequently digested with Dpn I and 
then transformed. (MassRuler DNA Ladder Mix, Thermo Scientific) 
 
PCR amplicon was then pooled and purified, treated with Dpn I to render inert any 
remaining supercoiled plasmid and then purified again. Mutated plasmids were then 
transformed into TopTen competent cells. Four or more colonies were chosen and DNA 
minipreps were made (figure 24). 
  
 
 
Figure 24.           Mutant plasmid minipreps. [Left] F440A DNA plasmid minipreps 1-4, F440Y 1-4 and 
F448A 1-4. These mutated plasmids were from transformed competent cells after PCR, Dpn I treatment and 
purification. [Right] Mutant plasmids F448Y 1-4. 
 
Plasmids were then sequenced and results confirmed the single point mutation with 1.5 
kB sequenced (Table 2). Using primers outside the prME region, the complete plasmid 
was then sequenced to confirm no other mutations, deletions or insertions occurred (see 
Appendix). Maxipreps were then made with Invitrogen Pure-link plasmid kit to ensure a 
high degree of purity without any endonuclease activity. 
 
 
 
 
2       3       4       5     6     7 
F440A(4)    F440Y(4)    F448A (4)                 F448Y (4) 
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 F422A  
W       D       A      G       S      L      G       G      V       F     T       S      I      G       K      A       L      H     Q       V      F      G        
CTG GGA GCC CGG CAG CCT GGG CGG CGT GTT CAC CTC CAT CGG AAA GGC CCT GCA CCA GGT GTT CGG  
   A      I       Y      G       A      A      F      S      G      V       S 
AGC CAT CTA CGG AGC CGC CTT CTC CGG CGT GTC C 
F429A 
  W      D      F     G       S       L     G       G      V       A      T      S       I      G       K      A      L       H     Q       V      F      G       
CTG GGA CTT CGG CAG CCT GGG CGG CGT GCC CAC CTC CAT CGG AAA GGC CCT GCA CCA GGT GTT CGG  
   A       I      Y      G       A      A      F      S      G      V       S 
AGC CAT CTA CGG AGC CGC CTT CTC CGG CGT GTC C 
F440A 
  W     D       F      G      S      L       G      G       V      F      T      S      I       G       K      A      L      H      Q      V       A      G       
CTG GGA CTT CGG CAG CCT GGG CGG CGT GTT CAC CTC CAT CGG AAA GGC CCT GCA CCA GGT GCC CGG  
  A        I     Y      G       A      A      F      S      G      V       S 
AGC CAT CTA CGG AGC CGC CTT CTC CGG CGT GTC C 
Y444A 
  W     D       F      G      S      L      G       G      V       F      T      S       I      G      K      A       L      H      Q      V       F      G       
CTG GGA CTT CGG CAG CCT GGG CGG CGT GTT CAC CTC CAT CGG AAA GGC CCT GCA CCA GGT GTT CGG  
  A       I       A      G       A       A      F      S     G       V      S 
AGC CAT GCC CGG AGC CGC CTT CTC CGG CGT GTC C 
F448A 
 W       D      F     G       S      L       G      G      V       F      T      S       I      G      K       A      L      H      Q      V       F      G       
CTG GGA CTT CGG CAG CCT GGG CGG CGT GTT CAC CTC CAT CGG AAA GGC CCT GCA CCA GGT GTT CGG  
  A       I       Y       G      A      A       A      S     G       V      S 
AGC CAT CTA CGG AGC CGC GCC CTC CGG CGT GTC C 
F422Y 
  W     D       Y      G      S       L      G      G      V       F      T      S       I      G      K       A      L       H      Q     V      F      G        
CTG GGA TAC CGG CAG CCT GGG CGG CGT GTT CAC CTC CAT CGG AAA GGC CCT GCA CCA GGT GTT CGG  
   A       I      Y      G       A      A       F     S      G       V     S 
AGC CAT CTA CGG AGC CGC CTT CTC CGG CGT GTC C 
F429Y 
  W     D       F      G      S      L       G       G     V       Y      T      S       I      G      K       A      L      H      Q      V       F     G        
CTG GGA CTT CGG CAG CCT GGG CGG CGT TAC CAC CTC CAT CGG AAA GGC CCT GCA CCA GGT GTT CGG  
   A       I      Y      G      A       A       F     S      G       V      S 
AGC CAT CTA CGG AGC CGC CTT CTC CGG CGT GTC C 
F440Y 
  W      D      F      G      S      L       G      G       V      F      T      S       I      G       K      A      L      H      Q      V       Y     G        
CTG GGA CTT CGG CAG CCT GGG CGG CGT GTT CAC CTC CAT CGG AAA GGC CCT GCA CCA GGT TAC CGG  
   A       I      Y      G      A       A       F     S      G      V       S 
AGC CAT CTA CGG AGC CGC CTT CTC CGG CGT GTC C 
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Y444F 
  W     D       F      G      S      L       G      G       V      F      T      S       I      G       K      A      L       H      Q     V       F      G       
CTG GGA CTT CGG CAG CCT GGG CGG CGT GTT CAC CTC CAT CGG AAA GGC CCT GCA CCA GGT GTT CGG  
  A       I       F      G      A       A       F     S      G       V      S 
AGC CAT TTC CGG AGC CGC CTT CTC CGG CGT GTC C 
F448Y 
  W      D      F      G      S       L      G      G       V      F      T      S       I      G       K      A      L      H      Q      V       F      G       
CTG GGA CTT CGG CAG CCT GGG CGG CGT GTT CAC CTC CAT CGG AAA GGC CCT GCA CCA GGT GTT CGG  
  A       I       Y      G       A      A      Y      S      G       V      S 
AGC CAT CTA CGG AGC CGC TAC CTC CGG CGT GTC C 
 
Table 2.           Mutant plasmid sequences. Mutants F/Y ! A showing the nucleotide change to GCC and 
the amino acid single point mutation. Mutants F/Y ! Y showing the change to TAC.or TTC and the single 
point mutations. Mutants were then sequenced for the complete prME region (see Appendix A).   
 
The single-point mutations (F422A/Y, F429A/Y, F440A/Y, Y444A/Y, F448A/Y) reside in 
ten separate NGC_prME_opt_neo plasmids, which allow for singular examination of the 
group substitutions previously made by the Young laboratory. The single amino acid 
changes were then examined for their role in structural changes of E, including prM 
heterodimeric formation and secretory pathway. 
420 
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CHAPTER 4 
RESULTS: CONSTRUCTION OF LENTIVIRAL PSEUDOTYPED PARTICLES 
4.1. Introduction 
For the second aim of this project, a lentiviral expression system was developed as an 
alternative fusion assay to test MPER E2 mutants. Two separate four-plasmid systems 
from Dr. Nigel MacMillan (Diamantina Institute, University of Queensland) and Dr. Rod 
Minchin (School of Biomedical Sciences, University of Queensland) were acquired and 
transiently co-transfected by calcium-phosphate precipitation into HEK 293T cells (refer 
to materials and methods section for description of this four-plasmid system). 
Transfection in HEK 203T cells results in lentivirus with the chosen envelope protein 
displayed (figure 25). These transduction-ready pseudotyped lentiviral particles infect 
target cells by fusion, which tests fusion capability. After uncoating and reverse 
transcription, the provirus is integrated, which results in the target cell stably expressing 
the reporter gene, eGFP. After viral RNA translation, assembly, and budding, mature 
lentivirus is released studded with the chosen envelope protein and expressing eGFP. 
 
 
Figure 25.  Development of lentiviral expression system. Pseudotyped lentiviral particles are made 
with the four-plasmid system containing either VSV-G or Dengue prME as the envelope protein. After these 
viral particles infect target cells (by fusion of pseudovirus to target cells), they then stably express the 
reporter plasmid eGFP. 
 
Wild-type prME was tested, along with the control envelope protein VSV-G (Vesicular 
Stomatitis Virus). These lentiviral supernatants were titrated neat or concentrated (up to 
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60-fold) with either HEK 293T or Vero cells. Cells were then tested for positive eGFP 
(green fluorescent protein) expression by flow cytometry. Development of this 
expression system initially failed to result in a reproducible, efficient system to test fusion 
of E2 mutants determined by wild-type prME results. In an attempt to optimise 
expression, several variables were individually modified, including transfection with or 
without polybrene addition; different ratios of plasmids; or small (T75) or large scale 
cultures (10+ T175 flasks) of HEK 293T cells. With these variables tested in conjunction 
or separately, GFP-expressing cells were, on average, less than 20% of the total cell 
population. The highest percentages were achieved with plasmids in the transfection 
ratio of (pREV: pRRE: pLL3.7: pMD.G) 1: 2.5: 4: 1.5, transduction with cells of low 
passage number (>15) and viral harvests that were relatively fresh (within 2 weeks). 
However, even after optimisation, repeat transductions resulted in large variations in the 
percentage of GFP positive cells. Twenty-five transfection trials were conducted to 
create the pseudotyped particles followed by transduction to test viral supernatants.  
 
4.2. Results: Transfection of cells to generate pseudotyped viral particles and 
transduction of cells to test viral particles with VSV-G or DENV prME 
Preliminary transductions with the VSV-G (positive control) pseudotyped particles were 
conducted on Vero cells and resulted in low percentages of cells taking up the virus 
(figure 26, A). The background level of fluorescence was 5.2%. Additions of viral 
supernatant ranging from 10-1 to 102.8 µl resulted in positive fluorescence, after 
background subtraction, peaking at 4.5% with 101 µl of virus supernatant. Samples 
should optimally have, at minimum, 10,000 viable cells to acquire a significant sample 
size for fluorescence versus background fluorescence. In this experiment, cells counted 
(“number of events”) were low, ranging from 785 to 1924, which indicated that the cells 
did not survive the preparation, or were lost, prior to reading. There was no causal trend 
with a larger volume of virus added; the higher volume of virus added did not increase 
the number of cells fluorescing. Subsequent trials with VSV-G and Vero or HEK 293T 
cells produced negligible percentages of positive cells ranging from 0-0.4% even with 
10,000 cells counted (data not shown). Without a stably fluorescing positive control in 
VSV-G, there is no comparative example for prME. 
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DENV prME viral supernatant was prepared and Vero cells transduced, which resulted in 
percentages of positive cells ranging from 1 to 13.4% for 101 µl with a possible best 
range of supernatant added from 101 to 101.9 µl (13.4 to 10.1%), (figure 26, B). Cells 
counted were higher with an average of 6400. Unfortunately, subsequent trials with 
DENV prME and VSV-G, prepared in parallel, produced fluctuating and low positive 
percentages acquired (data not shown). 
It was possible that the viral supernatants were too dilute, therefore, supernatants were 
concentrated in Vivaspin centrifugation columns (mwco 100,000) (N. Macmillan, 
personal communication). A concentrated VSV-G lentiviral supernatant was prepared 
and transduced into HEK 293T cells (figure 26, C). There was significant cell loss as 
depicted by the percentage of viable cells, which ranged from 2.3 to 3.6%, 0.4 to 1.3% of 
which were positively fluorescing. These low positive cell percentages were typical of 
many trials conducted with fresh or stored supernatant as well as secondary trials 
conducted immediately following promising results.  
A concentrated stock of prME was prepared and after HEK 293T cell transduction, 
higher percentages of positive cells were seen, which peaked at 53.6% with 1 µl of 10-2 
dilution (figure 26, D and E). The highest percentages were generally seen with the 
lowest amount of virus applied. This was repeated in three subsequent experiments with 
this stock of concentrated virus and results could not be replicated. This might indicate 
that the freshness of the supernatant is important or that the infective particles are 
unstable.  
 
 
  
A B 
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Sample 
Description Total % 
% Positive 
cells 
2-6 Mock 2.9  
1-1 10-2 dilution 56.5 53.6 
1-2 10-1 32.2 29.3 
1-3 100.5  µl 18.9 16 
1-4 100.7  µl 4.1 1.2 
1-5 101  µl 7.2 4.3 
1-6 101.3  µl 21.4 18.5 
2-1 101.6  µl 5.8 2.9 
2-2 101.9  µl 6.1 3.2 
2-3 102  µl 5.7 2.8 
2-4 1.2 x 102  µl 5 2.1 
2-5 2 x 102  µl 7.1 4.2 
 
Figure 26.  Flow cytometry of Vero cells transduced with prME lentiviral pseudotyped particles. [A] 
Vero cells transduced with the control VSV-G. Cells were transduced with neat preparations of viral 
supernatant from 0 – 1 ml. The % Total is the percent of viable cells detected and fluorescing and % positive 
cells is percentages with background (mock) subtracted. Results were variable, with the highest percentage 
at 4.5% (Standard deviation (SD) = 1.86). [B] Vero cells transduced with prME. Cells were titrated with viral 
supernatant neat from 0 – 1 ml. Results were variable, with the highest percentage at 13.4% (SD = 4.06).  
[C] Vero cells transduced with concentrated VSV-G. Cells were transduced with neat preparations of viral 
supernatant from 0 – 101.4 µl. Results varied from 1.3 to 0.4% with 10,000 cells counted (SD = 0.42). [D + E] 
Vero cells transduced with concentrated prME. Cells were transduced with viral supernatant 2 x 102 µl neat 
to 10-2 dilutions. Results varied from 53.6 to 1.2%, with a trend towards the highest percentage of positive 
cells for the lowest amount of virus (10-2 dilution) with one exception at 101.3 µl of supernatant (SD = 16.32).  
 
Pseudotyped lentiviral particles of VSV-G and prME were tested together with 
supernatant titrated from neat to 125-fold dilutions (figure 27). VSV-G supernatant did 
not show any positive fluorescing cells while prME gave a low positive percent 
population from 0.1 to 1.6%. These results show, again, the low positive percentages 
often achieved even with fresh lentiviral supernatant. 
Concentrated lentiviral supernatant of wild-type prME was then tested on Vero cells 
(figure 27). Supernatant was added at 101.7 µl and in subsequent 5-fold dilutions to 2.4 x 
10-4 µl. This transduction showed a clear trend with 2 and 5.2% positive cells at the 
highest volume added followed by a peak of 12.3% at the 25-fold dilution and a following 
D 
E 
C 
 60 
decline in positive percentages. This transduction was repeated with the supernatant but 
percentages were low or negligible. 
 
 
 
prME in Vero cells TU/ml calculated 
µl added % positive No. of cells 
No. of positive 
cells per ul TU/ml 
5 x 101 2 1.28x106 25600 512 5.120x105 
1 x 101 5.2 1.28x106 66560 6656 6.656x106 
100.3 12.3 1.28x106 157440 78720 7.872x107 
4x10-1 5.6 1.28x106 71680 179200 1.792x108 
8x10-2 3.7 1.28x106 47360 592000 5.920x108 
1.6x10-2 2 1.28x106 25600 1600000 1.600x109 
3.0x10-3 0.4 1.28x106 5120 1706667 1.707x109 
6.0x10-4 2.4 1.28x106 30720 5.1E+07 5.120x1010 
1.2x10-4 1.6 1.28x106 20480 1.7E+08 1.707x1011 
2.4x10-4 1.6 1.28x106 20480 8.5E+08 8.533x1011 
 
Figure 27.  Flow cytometry of HEK 293T cells transduced with lentiviral pseudotyped particles with 
VSV-G or prME. [A Left] Results for prME varied from 0.1% to 1.6% (SD = 0.71). There were no cells 
fluorescing with VSV-G. [A Right] Flow cytometry of Vero cells transduced with lentiviral pseudotyped 
particles with a concentrated stock of prME. Cells were transduced with 5-fold dilutions of concentrated 
supernatant. Results show a peak at the 25-fold dilution of 12.3% with a steady decline with subsequent 
dilutions (SD = 3.45). [B] The viral TU/ml was calculated by taking the percentage of positive cells, the 
number of cells processed and volume.  
 
A concentrated stock of VSV-G lentiviral supernatant was prepared and tested with HEK 
293T cells. When lentiviral dilutions were compared with the mock control, there was no 
population of cells fluorescing. Figure 28 shows the percentage of non-viable cells 
detected by the cytometer, which is designed to find viable cells that are the correct 
morphology, i.e. intact and spherical. The graph shows the mock sample with 15% non-
viable cells but with lentiviral supernatant added, that percentage increases dramatically 
to 47.8 – 68.5% with the highest volume added, only decreasing at the 10-1 dilution. In all 
A 
B 
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experiments prior to this, the positive population was taken from the viable cell 
population count. This shows that with the addition of lentivirus, large populations of cells 
die, either by exocytosis of the virus or apoptosis after transduction.  
 
 
 
Figure 28.  Flow cytometry of Vero cells transduced with a concentrated stock of VSV-G lentiviral 
pseudotyped particles. Cells were transduced with neat preparations of viral supernatant from 30 to 10-5 µl 
dilutions. Results show that there is no positive cell population with the addition of supernatant. With the 
addition of lentivirus, the non-viable cell count increases dramatically to 47.8 to 68.5%, which shows that 
large populations of cells do not survive transduction (SD = 1.33).  
 
4.3. Results: Luciferase reporter system 
4.3.1. Luciferase plasmid cloning     
Since flow cytometry gave low and irreproducible results, an alternative system was 
developed by replacing eGFP with luciferase. This was an attempt to generate a more 
sensitive detection system. This could negate the deleterious handling effects that occur 
with FACS as well test an alternative reporter gene. This four plasmid system was 
developed by cloning luciferase (Photinus pyralis, pGL-3c, Invitrogen) into pLL3.7. 
Pseudotyped particles were produced and tested for luciferase activity on a luminometer. 
Harvests of lentivirus were tested for cell cytotoxicity with an MTT assay (data not 
shown). 
To generate pLL3.7_luc+, pLL3.7 was digested with Nhe I and Pci I, which results in a 
6925 bp vector and a 724 bp insert containing eGFP. Double-digested pGL-3 results in a 
2239 (which contains the luciferase gene) and a 1683 bp band (figure 29). These two 
bands were gel extracted, ligated and transformed into TopTen competent cells. The 
new luciferase reporter plasmid is 9164 bp in length and was named pLL3.7_luc+. 
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Figure 29.  pLL3.7_luc+ cloning plasmids digested. The first band is pLL3.7 uncut, followed by pLL3.7 
digested with Nhe I and Pci I resulting in 6925 and 724 bp bands. The third band is uncut pGL3c, followed 
by the plasmid digested with Nhe I and Pci I, which results in 2239 and 1683 bp bands. The 6925 bp and 
2239 bp bands were gel extracted and ligated together to produce a 9164 bp vector (pLL3.7_luc+) 
 
Twelve colonies were picked from this transformation and these colonies were digested 
with diagnostic restriction enzymes BamH I (which cuts only pLL3.7) and Ava I (which 
cuts inside the luciferase gene) (figure 30). Ava I cuts at 7075, 2311, 2951, and 4831 
resulting in 4329, 650, 1862, and 2262 bp bands (without the luciferase gene there are 
only three bands 4329, 650, and 4124 bp in length). Two colonies had the correct 
products and were sent to sequencing, which resulted in a positive insertion of the 
luciferase gene for Clone 6.  
 
 
 
Figure 30.  pLL3.7_luc+ cloning plasmids digested. Eight possible pLL3.7_luc+ clones digested with 
diagnostic restriction enzymes. The first band is uncut (U), the second band is BamH I digested (B) and third 
band is Ava I digested (A). There are two possible clones (6 and 9), which show the correct band sizes. 
Clones 6 and 9 do not have the 4124 bp band, which has been cut into 1800 and 2262 bp bands. 
 
4.3.2. Luciferase substrate assay   
To test this new pLL3.7_luc+ reporter plasmid, several plasmids were transfected in 
parallel into PS-EK cells: pGL-3b (“basic”, negative control), pGL-3c (“control”, positive 
pLL3.7          pGL-3 
uncut    cut   uncut  cut 
4329 
2262 
 
1800 
 650 
Clone 2   Clone 3   Clone 6    Clone 7   Clone 9   Clone 10   Clone 11  Clone 12 
U    B    A    U   B   A   U    B    A    U   B   A   U    B    A    U   B    A    U   B   A    U   B   A    
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control containing the luciferase gene), pCI (empty, negative control) and pLL3.7_luc+. 
Luciferase activity was detected with pLL3.7_luc+ values ranging from 4-7 RLUs/ml 
(reflecting light units/ml) and pGL-3b (negative) at 0.2 (table 3). Repeating this 
experiment, higher values were detected with pLL3.7_luc+ ranging from 39 to 51, pGL-
3c (positive control) from 14 to 20, significantly lower than the pLL3.7_luc+ clone while 
background levels were very low, ranging from 0.2 to 0.8 (table 4).  
 
pGL-3b (neg) pCIneo (neg) pLL3.7_luc+  
Clone 6 
pLL3.7_luc+  
Clone 9 
Mock 
0.272 0.938 4.110 4.871 0.515 
0.287 1.135 7.451 4.598 1.026 
0.267 1.023 5.598 3.515 0.742 
0.244 0.564 4.617 5.724 1.312 
Averages     
0.268 0.915 5.444 4.639 0.899 
 
Table 3.  Luciferase readings for the transfection trial of controls. The second trial in RLUs/ml shows 
four replicates for each sample. pCI and mock (lipofectamine with no DNA) samples were approximately the 
same. pGL-3 is clearly not expressing luciferase and appears to be a good negative DNA control. pLL3.7 
luc+ clones number 6 and 9 have values that are reproducible. 
 
pGL-3b 
(neg) 
pGL-3c  
(pos) 
pLL3.7_luc+ 
Clone 6 pCIneo (neg) Mock + lipo Mock (blank) 
0.768 16.58 44.25 1.301 0.674 0.202 
0.828 19.97 39.23 1.313 0.423 0.188 
0.856 14.96 51.61 1.232 0.479 0.218 
0.81 18.91 39.3 1.11 0.412 0.161 
Averages           
0.82 17.61 43.60 1.24 0.50 0.19 
 
Table 4.  Luciferase readings for transfection trial of controls. Readings are in RLUs/ml showing four 
replicates for each sample. pGL-3b is the negative control plasmid. pGL3-b is the positive control plasmid. 
pLL3.7_luc+ is the lentiviral reporter vector containing luciferase in lieu of eGFP. pCI is the original cloning 
vector for the DENV NGC prME clones. Mock (+lipo) is no plasmid but with the lipofectamine transfection 
solution and mock (blank) is without. There is a 50-fold difference between pGL-3b and pLL3.7 luc+ and a 
2.5-fold increase from the positive control pGL-3c to the clone. 
 
This luciferase reporter plasmid was then tested in the lentiviral packaging system with 
the three other lentiviral plasmids. HEK 293T cells were transiently co-infected with the 
four lentiviral expression constructs pRRE (packaging), pREV (Rev-expression), pMD.G 
(VSV-G envelope), and the new luciferase expressing pLL3.7_luc+ reporter plasmid. 
Two controls were prepared with pGL-3b (basic, no luciferase activity) or pGL-3c 
(control, positive luciferase activity) used in lieu of pLL3.7_luc+. Two independent 
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preparations failed to give detectable luciferase activity, and time course and dose 
response did not improve this. After a longer incubation during transduction (from two 
hours to overnight) and activity tested later (from overnight to two days), no luciferase 
activity could be measured (table 5).  
 
Replicate 101.7  µl 100.7  µl 1 x 101  µl 2 x 101  µl 5 x 101  µl 0 µl 
1 0.014 0.016 0.016 0.014 0.02 0.015 
2 0.01 0.016 0.014 0.016 0.014 0.014 
3 0.012 0.018 0.016 0.016 0.014 0.014 
4 0.011 0.010 0.012 0.010 0.010 0.011 
SD 0.0017 0.0035 0.0019 0.0028 0.0041 0.0017 
 
Table 5.  Luminometer readings for Vero cells infected with VSV-G lentiviral supernatant from 0 to 
50 µl. There were no recordable levels of luciferase activity. The subsequent two trials of VSV-G with 
pLL3.7_luc+, pGL-3b or pGL-3c were also negative. 
 
4.4. Discussion 
4.4.2. Conclusions of the lentiviral expression system 
There are several challenges when using lentiviral systems. At transfection, cells must 
take up all four lentiviral plasmids, and expression must be sufficient for infectious 
particles to assemble. The supernatant generally does not have enough lentivirus 
present for efficient transduction, it must be concentrated and be relatively fresh, within 1 
or 2 days old. Cells must withstand transduction of lentivirus and remain intact through 
fixing and washing. When the same conditions were used in replicate transductions, 
percentages of fluorescing cells would vary. A concentrated stock of prME resulted in the 
highest percentage of cells fluorescing, peaking at 53.6% with 1 µl of the 10-2 dilution. 
Yet, when this experiment was repeated the percentage of cells fluorescing was low or 
negligible. The control protein, VSV-G was concentrated and tested in several 
transductions. These resulted in low percentages of cells fluorescing, from 0 to a 
maximum of 2%. Since the control protein would not make functional pseudotyped 
particles, there is no stock of lentivirus to compare wt prME, and subsequently, prME 
mutants to. It would be challenging to compare changes in protein expression and 
fluorescence between MPER E2 mutants, which may be relatively minor, given these 
inherent problems. It is possible that there is not enough lentivirus to survive even short-
term storage, either at 4°C or -20/-80°C without a freezing buffer. This system would be 
best applied by maintaining a live positive cell population by cell sorting. As it is, a large-
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scale, high-volume (ten T175 flasks) harvesting method must be used, which is 
cumbersome and costly. In total, 25 transfection trials were conducted to create the 
pseudotyped particles followed by transduction to test viral supernatants resulting in non-
reproducible and inconsistent results. This system has proven successful with a related 
flaviviridae, Hepatitis C although it has been proposed that Hep C E1E2 glycoproteins 
are distinctly separate from other flaviviruses [36, 73, 83-88]. Hep C is phylogenetically 
related but not analogous to prME, as E1 has been compared to Class I fusion proteins, 
whereas E2 is classified as a Class II glycoprotein [36, 89, 90]. E1E2 has an ER 
retention signal, as does prME but a fraction of E1E2 is not retained and migrates to the 
cell surface. This protein is then available for pseudotype particle formation [91, 92]. 
E1E2 does not have a maturation pathway that involves proteolytic cleavage of pr from E 
that Dengue does. The maturation of E1E2 involves medial or trans-Golgi localised 
glycosylation and not enzymatic cleavage, also resulting in protein available for 
formation of HCVpp (Hepatitis C pseudotyped particles) [93]. Our theoretical design was 
based upon the Drummer laboratory’s (Burnett Institute) success with HCVpp [personal 
communication]. There are a few key differences in this system, which has been shown 
to be detrimental to prME lentiviral generation. The HCVpp system involves a three-
plasmid, luciferase reporter assay, which results in a higher amount of transfection 
efficiency (three versus four plasmids) and possibly a large difference in the amount of 
lentivirus generated [91]. Not being GFP-based, the luciferase assay is more sensitive, 
although it is level PC3. It is also possible to lyse the transduced cells to quantify 
lentiviral generation within the cell as well as cell-surface expressed protein. Thirdly, 
HCVpp was harvested at three days and not the following day [72, 91], which could be 
crucial in the level of virus produced. Our plasmid pLL3.7_luc+ was cloned, substituting 
the luciferase gene for GFP (level PC2). The clones produced fluorescing cells with the 
luciferase assay. The plasmid was then used in the four-plasmid lentiviral packaging 
system but when assayed, this transfection did not produce any luciferase activity, 
indicating that there were no lentiviral particles made. For future direction, the three-
plasmid PC2 HCVpp system could be used to clone prME in place of VSV-G. Lentivral 
particles should be harvested after three days and concentrated. Generation of 
pseudotyped particles would then be tested with the luciferase assay. All ten MPER E2 
mutants would then be cloned in place of wt prME and tested to compare their fusion 
ability. 
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CHAPTER 5 
RESULTS: EXPRESSION OF prM AND E IN MAMMALIAN CELLS 
5.1. Introduction 
The third aim of this project was to investigate and characterise the structure of wild type 
and MPER E2 mutants in a mammalian cell line. Since the results for the lentiviral 
expression system were inadequate, the mutants were transfected into a mammalian 
cell line to compare expression and localisation. FACS analysis was used to detect and 
quantify cell surface expression (section 5.2). Two monoclonal antibodies, 4G2 (α-E 
fusion peptide) and 3H5 (α-E domain I and III linker) conjugated with Alexa Fluor 488 
were used to probe transfected and infected cells. Protein expression of prME was 
confirmed by SDS-PAGE and Western immunoblot (section 5.3). All ten MPER E2 
mutants (F422A/Y, F429A/Y, F440A/Y, Y444A/F, and F448A/Y) were transfected along 
with wild-type prME, negative pCI, and infected controls. To confirm in-cell prME 
expression, localisation, and cell surface trafficking, MPER E2 mutants were analysed by 
immunofluorescence with multiple trials of transfected and infected (NGC DENV-2) PS-
EK, Vero and HEK 293T cells (section 5.4). Cells were visualised under confocal laser-
scanning microscopy (Zeiss LSM 510 Meta Confocal Microscope). Several molecular 
probes were also examined to study prME expression and progression through the 
secretory pathway (section 5.5).  
 
5.2. Results: Analysis of cellular and surface expressed prM and E 
5.2.1. Flow cytometry of transfected cells to quantify cell surface 
expression 
Plasmids containing prM and E wild type and mutants were transfected into PS-EK, HEK 
293T and Vero cells as described in the Materials and Methods section. To determine 
whether these proteins were expressed, cells were assayed by flow cytometry using 
murine monoclonal 4G2 (against E fusion peptide) and 3H5 (which recognises the E 
domain I and III linker) followed by Alexa-488 conjugated goat anti-mouse IgG. All ten 
MPER E2 mutants were tested along with wild-type prME and negative pCI (empty 
vector) controls. Results showed positive fluorescence but were inconsistent, showing a 
lack of reproducibility similar to that found with the lentiviral pseudotype particle system. 
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Background levels were first tested with infected PS-EK cells and 3H5 or 4G2. The 
fluorescence levels with these two antibodies were significantly higher compared with 
minimal background levels of Alexa Fluor 488 or no conjugate (figure 31). 
 
      Background            Alexa-only background 
  
 
α-E 3H5    α-E 4G2 
  
 
Figure 31.  Flow cytometry analysis of infected PS-EK cells. Background controls to set thresholds for 
fluorescence. Top panel is background fluorescence with or without Alexa Fluor 488. The bottom two 
histograms show E protein monoclonal antibodies 3H5 (α-E domain I and III linker) and 4G2 (α-E fusion 
peptide), both of which show good levels of fluorescence compared to the background. 
 
PS-EK cells were then transfected with pCI, wt prME and all ten E2 mutant plasmids 
(F422A/Y, F429A/Y, F440A/Y, F448A/Y, Y444A/F. Cells were seeded in six-well plates 
with 2 x 105 cells/ml and transfected with 1 µg of DNA and 3 µl of Lipofectamine-2000.  
Five hours post-transfection, transfection media was taken off and complete media was 
added. Cells were fixed the following day (24 hours post-transfection) and wells were 
probed with 3H5 and Alexa Fluor 488.  Antibody 3H5 was chosen, as it has previously 
been shown to be a better antibody to use with FACS (table 6) [94]. Alen, et al. (2009) 
compared antibody 3H5 to 4G2 in flow cytometry experiments and 3H5 had a higher 
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mean fluorescence of intensity with DENV-2 NGC. Cells were counted to 10,000, viable 
cells determined by their spherical morphology, “% Positive cells” are the subset of 
viable cells that are fluorescing, and “Positive % Total” is the percent of total cell counts 
that were positive. Background (pCI) was around 1% and wt prME showed 6% positive 
fluorescence. The E2 mutants ranged from 1.7 to 9.2% positive fluorescence 
(background subtracted), in line with wild-type prME, which showed that E protein could 
be tracked through flow cytometry in transfected cells with this antibody. There was a 
loss of cell counts with the E2 mutant transfections but only minimal difference to cell 
viability. This may have skewed the results, especially when the viable cell percentage 
was low (i.e. E2 mutant F440Y).  
 
Sample 
 
% Viable 
Cells 
% Positive 
Cells Positive % Total Cell Count 
pCI 40.8 2.4 1 10000 
prME 42.7 14.1 6 10000 
F422A 28.2 10.6 3 10000 
F422Y 25.4 12.2 4.3 3137 
F429A 37.1 9.4 3.5 3377 
F429Y 34.3 22.2 7.6 4013 
F440A 33.7 27.1 9.2 3450 
F440Y 14.4 11.8 1.7 1886* 
Y444A 31.4 25.9 8.1 3140 
Y444F 35.6 13.2 4.7 5537 
F448A 38.6 14.1 5.4 4179 
F448Y 37.3 10.3 3.8 7902 
 
Table 6.  FACS analysis of permeabilised PS-EK cells transfected and probed with 3H5. The 
controls pCI and wt prME and all ten E2 mutants and probed with 3H5. Background (pCI) was about 1% and 
wt prME was 6% positive fluorescence. The E2 mutants ranged from 1.7 to 9.2 % positive, which showed 
that E protein could be tracked through flow cytometry in transfected cells with monoclonal antibody 3H5. 
(SD = 2.43, mutants only) 
*Low cell count for this sample 
 
The cell counts were not all 10,000, therefore, this experiment was repeated to attain 
higher intact cell numbers. The results were consistent with the above data (table 7). 
Non-permeabilised cells, as expected, showed low levels of fluorescence (0 – 1.2%) 
whereas permeabilised cells ranged from wt prME at 4.7% positive fluorescence (similar 
to 6% previously seen) while the E2 mutants ranged from 0.2 to 16.2 % fluorescence, 
which was marginally higher. This experiment was repeated five times with fluctuating 
percentages of positive cells – either cell pellets were lost and cell count too low for 
detection or positive fluorescence levels too low to see any difference between 
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background, positive controls and E2 mutants (table 8). If there are any differences 
between wild-type and the E2 mutants, FACS analysis would be too inconsistent to allow 
for detection in non-permeabilised cells, as was the case with lentiviral infection. This 
method of quantification may benefit from harvesting cells at three days instead of one 
day post-transfection, again similar to lentiviruses. There appears to be a low, but 
detectable level of E expressed at the cell surface in non-permeabilised cells, whereas 
with permeabilised cells, E levels significantly higher. Fluorescence may increase if cells 
were harvested later to allow for E trafficking to the cell surface. Cell preparations for 
flow cytometry are very different than the procedure for confocal immunofluorescence 
and similar to the lentiviral pseudotype particle FACS analysis. After transfection, cells 
were scraped off the bottom of plates, centrifuged and fixed. Cell pellets were then 
blocked and probed by indirect fluorescence. There is usually a large amount of cell loss 
through this procedure due to multiple washing steps, which leads to variable results in 
comparison with immunofluorescence, which starts from fixed cells after infection or 
transfection. Results are therefore inherently variable; cell counts and fluorescence are 
positive in one experiment and then too low for detection in the following experiment. 
Ideally, confocal immunofluorescence and FACS-prepared samples would be tested in 
parallel to confirm transfection efficiencies and to compare the two detection methods. 
Confocal immunofluorescence was conducted to confirm expression and localisation of 
prME (section 5.4). While confocal microscopy provides a good comparison of wild-type 
prME and MPER E2 mutants, it requires subjective quantification, which FACS does not. 
 
  Sample Viable Cells Positive % Total (-) Background 
Non-perm pCI 22.4 0.7   
  prME 20.4 0.7 0 
  F422A 18.9 0.8 0.1 
  F422Y 20.8 0.9 0.2 
  F440A 20.2 0.8 0.1 
  F440Y 17.7 1.4 0.7 
  Y444A 18.9 1 0.3 
  Y444F 21.5 0.9 0.2 
  F429A 21.7 0.6 -0.1 
  F429Y 20.5 0.6 -0.1 
  F448A 23.8 1 0.3 
  F448Y 26.1 1.9 1.2 
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Perm pCI-perm 28.3 2.2   
  prME-perm 20.7 6.9 4.7 
  F448A-perm 15.5 5.2 3 
  F448Y-perm 25.6 18.4 16.2 
  F422A-perm 15.7 2.4 0.2 
  F422Y-perm 15.6 3.3 1.1 
  F429A-perm 17.9 6.4 4.2 
  F429Y-perm 18.4 5.7 3.5 
  Y444A-perm 13.5 3.4 1.2 
  Y444F-perm 17.5 5.4 3.2 
  F440A-perm 20 6.7 4.5 
  F440Y-perm 22.2 14 11.8 
 
Table 7.  FACS analysis of PS-EK cells transfected with the controls pCI and wt prME and all ten 
E2 mutants and probed with 3H5/488. Cell count was 10,000 for all samples. Wild-type prME, permeabilised 
cells showed 4.7% positive fluorescence (similar to 6% previously seen) while the E2 mutants ranged from 
0.2 to 16.2 % fluorescence, which was marginally higher than seen previously (SD = 5.11, permeabilised 
mutants only). 
 
Sample Cell Count Viable Cells Positive % Total (-) Background 
pCI 6987 6.1 1.9   
prME 1054 6.9 2.7 0.8 
F422A 10000 10.8 2.6 0.7 
F422Y 10000 11.8 2.2 0.3 
F429A 5909 7.9 2.8 0.9 
F429Y 5959 7 2.6 0.7 
F440A 10000 9.2 2.2 0.3 
F440Y 4020 9.5 1.3 -0.6 
Y444A 10000 13.1 2.7 0.8 
Y444F 3781 5.2 1.5 -0.4 
F448A 3878 7.3 2.8 0.9 
F448Y 1178 8.8 1.9 0 
 
Table 8.  FACS analysis of non-permeabilised PS-EK cells transfected with the controls pCI and wt 
prME and all ten E2 mutants and probed with 3H5/488. Viable cell levels (and subsequently fluorescence) 
were very low and there appeared no differences between wt prME and E2 mutants. Cells should be 
permeabilised to reach minimal detection limits. (SD = 0.54, mutants only) 
 
5.2.2. In-cell detection of prM and E 
Due to the variable detected fluorescence with flow cytometry, another system for 
quantifying fluorescing cells was investigated. A GE in-cell analyser combines the 
visualisation of confocal microscopy with a quantifiable analysis of positive cells, similar 
to flow cytometry. A further advantage with this machine is its high-throughput capability 
to test multiple replicates at the same time with its 96-well plate format as well as the 
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ability to test live or fixed cells. Transfected PS-EK cells were tested on the GE in-cell 
analyser. All ten E2 mutants were individually transfected into PS-EK cells along with 
wild-type prME and pCI. Cells were seeded in 96-well plates with 1 x 105 cells/50 µl and 
transfected with 0.4 µg of DNA and 1 µl of Lipofectamine-2000.  Five hours post-
transfection, transfection media was taken off and complete media was added. Cells 
were fixed the following day (24 hours post-transfection) and wells were probed with 
Hoechst (1:10,000) and either 1:400 or 1:600 α-E 4G2 or 3H5 and Alexa Fluor 488. Cells 
displayed detectable fluorescence, with approximately half of cells positive (figure 32). 
With this imager, it is possible to automatically quantify fluorescence by subtracting cells 
that were not transfected (background). This can be accomplished only with an 
additional dye, such as DAPI or Wheat Germ Agglutinin (WGA). This method of 
detection appeared promising but experimentation was set aside to complete the other 
aims of the project.  
 
  
 
Figure 32.  GE in-cell analyser images of PS-EK cells. Cells were transfected with wild-type prME as 
an example of machine output. Cells were fixed and probed with 3H5 or 4G2, Alexa Fluor 488 and Hoechst. 
The imager took four fields of view per well and one field is shown as an example of wt prME probed with α-
E 4G2 [A] Phase contrast microscopy, [B] α-E 4G2 and Alexa Fluor 488 immunofluorescence. 
 
A B 
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5.3 Results: Detection of E protein production with SDS-PAGE and Western 
immunoblot 
PS-EK cells were transfected with wild-type prME along with the ten MPER E mutants to 
determine protein expression as well as correct conformation with epitopes available for 
antibody binding. Immunoblot experiments were undertaken to compare wild type with 
mutant polyprotein expression. Binding of monoclonal antibodies 3H5 and 4G2 was also 
compared. An infected cell control sample was used (m.o.i. = 1, 24 hour infection). DTT 
was used in the treatment of samples with monoclonal antibody 3H5, which cross reacts 
with the linker between domains I and II and thus, requires a linearised protein without 
disulfide bonds. DTT is not required with 4G2 as it binds with the α-E fusion peptide.  
 
α-E Monoclonal Antibody 4G2 
As detected by 4G2 α-E antibody, all mutants except F422A were expressed in PS-EK 
cells (E protein band at 65kDa, figure 33). Expression levels were variable with F429A 
and F429Y mutants showing the highest expression. A secondary band appears above 
65 kDa with the infected control, mutant F448A, and possibly mutant Y444A. This has 
been seen with other E protein gels and is thought be a difference in glycosylation of the 
envelope protein [P. Young communication]. 
The F448Y band migrated faster than wild-type prME but in line with the infected control 
sample (figure 33, [B]). It is unclear whether or not this is a gel artifact or true migration 
difference due to glycosylation. 
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Figure 33.  Western immunoblot of transfected PS-EK cell samples. [A] All F/Y ! A mutants with 4G2 
antibody. Distinct E-sized (~50 kDa) bands are shown for wt prME, F429A, F440A, Y444A, F448A (two 
bands) and infected control. There is no band for F422A. [B] All F/Y ! Y/F mutants with 4G2 antibody. 
Distinct E-sized bands are shown for wt prME, F422Y, F440Y, Y444F, F448Y, and infected control. pCI 
negative control shows no 4G2 binding.  
 
 
α-E Monoclonal Antibodies 3H5 and 4G2  
Transfected cell samples were then incubated in parallel with 4G2 (without DTT) and 
3H5 (with DTT). Transfected samples for 3H5 antibody were heat treated with DTT 
present in the SDS-PAGE loading buffer to break the disulfide bridges present in the 
secondary structure of E. Epitopes present in wild-type prME and the infected control 
sample bound 4G2 well (prME shows two E bands, which may be the glycosylated 
version of E, figure 34, [A]). pCI negative control again did not show 4G2 binding. MPER 
E mutants F429A, F440A, Y444A, F448A bound 4G2 well while F442A did not, which 
confirms the results above. Mutant Y444A appears to run faster here than figure 33A; 
this may be a molecular weight difference due to less glycosylation of the protein. It does 
migrate in line with wt prME lower band. MPER E mutants F422A (strong binding), 
F429A and F440A (moderate binding), bound 3H5 while Y444A and F448A showed 
weak binding (figure 34, [B]).  
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α-E 3H5, F/Y ! A mutants, with DTT  
 
 
Figure 34.  Western immunoblot of transfected PS-EK cell samples, all F/Y ! A/F mutants. [A] The 
top gel is of 4G2 detection with bands shown for wt prME (two bands), F429A, F440A, Y444A, F448A and 
the infected control. No bands are seen for F422A and pCI. [B] The bottom gel shows 3H5 detection. There 
were distinct E-sized bands seen for wt prME (two bands), F422A, and the infected control. There may be 
weak binding with F429A and F440A. 
 
MPER E mutants F422Y, F429Y, F440Y, Y444F, F448Y bound 4G2 well, which 
confirmed previous results. When samples were probed with 3H5, MPER E mutants 
F422Y, F429Y, Y444F and F448Y showed moderate binding while F440Y showed 
strong binding (figure 35). 
 
α-E 4G2, F/Y ! F/Y mutants, without DTT 
 
α-E 3H5, F/Y ! F/Y mutants, with DTT 
 
Figure 35.  Western immunoblot of transfected PS-EK cell samples, all F/Y ! Y/F mutants. [A] The 
top gel is of 4G2 detection with bands shown for F422Y, F429Y, F440Y, Y444F, F448Y and the infected 
control. The band for wt prME is faint and there is no band for pCI. [B] The bottom gel is 3H5 detection 
showing a distinct band for wt prME and the infected control. There are bands for F422Y, F429A, Y444F and 
F448Y and a strong band for F440Y.  
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As this system was optimised for cell lysis (lytic buffers), immunoblot transfer 
(submerged or semi-dry), and antibody incubation (length and volume), there was some 
loss during handling of the viscous protein samples and gel artifact shown. To 
summarize mutant protein expression, MPER E mutants F429A, F440A, Y444A, F448A 
showed good levels of binding with 4G2 while F442A did not. A secondary band appears 
above 65 kDa with the infected control and mutant F448A. This is thought to a difference 
in glycosylation of the envelope protein. MPER E mutants F422Y, F429Y, F440Y, 
Y444F, and F448Y all showed binding with 4G2, while the F448Y band migrated lower 
than wt prME but in line with the infected control sample. It is unclear whether or not this 
is a gel artifact or again, true migration due to glycosylation. To confirm this, protein 
samples could be standardised to compare identical quantities. With antibody 3H5, 
F422A showed a high expression level unlike with antibody 4G2. There may be a 
conformational preference for the 3H5 epitope between DI and DIII, due to F422’s 
position between the E1 and E2 helices. With the alanine substitution, 4G2 binding is 
reduced either by reduction in protein expression or conformational epitope loss. MPER 
E mutants F422Y, F429Y, F440Y, Y444F and F448Y all showed good binding with 3H5, 
while bands for F440Y were stronger than with the other mutants. 
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5.4. Results: Detection of in-cell and surface expressed E protein production 
with confocal microscopy 
5.4.1. Analysis of cellular and surface expressed E protein production in 
transfected cells 
To track E maturation and progression through the secretory pathway after protein 
expression was confirmed as above, MPER E mutant plasmids were transfected into 
PS-EK cells and probed with monoclonal antibodies for immunolocalisation. Cells were 
seeded on coverslips in 24-well plate format and transfected for confocal microscopy 
imaging. Twenty-four hours post-transfection, cells were either fixed or fixed and 
permeabilised. Optimal concentrations of α-E 4G2 (1:400 dilution) and Alexa Fluor 488 
(1:400 dilution) were determined by a comparison of 1:200 to 1:800 dilution series. 
Nuclei were stained with a Hoechst.  
PS-EK cells were first transfected with controls wt prME and pCI and all ten MPER E 
mutants and non-permeabilised, fixed cells were probed with 4G2 (figure 36). 
Efficiencies of 1 µg plasmid transfected were determined by counting fluorescing cells, 
subtracting from the total cell population in three visual fields and averaged (one image 
sample shown). Transfection efficiencies were close to the wild-type prME (92% of cells 
positive) as detected by 4G2, while mutants ranged from 77 to 85%. F422A was the 
exception at 49% positive cells. The number of perinuclear foci of E protein fluorescence 
was also averaged. For wild-type prME this was 33%, while mutants ranged from 7 to 
19%, except for F422A, which was zero. The lack of detection of F422A compared with 
the other mutations is consistent with the Western immunoblot data.  
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 % positive cells 
% perinuclear 
staining 
 % positive cells % perinuclear 
staining 
wt prME 92 33 F440A 77 12 
pCI (neg) 5 0 F440Y 85 12 
F422A 49 0 Y444A 83 8 
F422Y 79 19 Y444F 85 14 
F429A 85 7 F448A 77 8 
F429Y 84 10 F448Y 82 14 
 
Figure 36.  Immunofluorescence confocal microscopy of transfected non-permeabilised PS-EK cells 
probed 4G2 (green) and Hoechst (1:20,000, red). The transfection efficiency was calculated as an average 
of three images per sample (all images not shown). Background fluorescence was negligible (pCI, 5%) and 
wild-type transfection, prME was good (92%) while mutants ranged from 49% (F422A) to 85% (SD = 10.88, 
mutants only). There was evident perinuclear foci with the wild type prME at 33% and mutants ranging from 
7-19%, with none shown for F422A (bottom table).  
 
20 µm 
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Transfection of PS-EK cells (non-permeabilised), probed with Cholera toxin 
To make sure homogeneous fluorescence was background (Alex Fluor 488), a 
membrane marker for lipid rafts (Cholera Toxin Subunit B) was tested in conjunction with 
4G2/488. With the plasma membrane stained, fluorescence seen outside the cells would 
not be expression of E. PS-EK cells were transfected with controls wild-type prME and 
pCI (empty vector) and the MPER E mutants and not permeabilsed. Cells were probed 
with 4G2/488 (1:400 dilution), Cholera toxin subunit B (Tx-B, (1:500 dilution, 0.5 µg/µl 
solution), and 1:20,000 Hoechst. Fluorescence of controls and mutants were comparable 
to figure 36 and there is a clear difference between homogeneous staining of the 
cytoplasm and perinuclear staining (figure 37). Cholera Tx-B shows inconsistent staining 
(in blue), likely due to dye precipitation. Mutant F422A did not show 4G2 binding 
localised to the nuclei while all other mutants did.  
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Figure 37.  Immunofluorescent confocal microscopy of PS-EK cells transfected with wt prME (positive 
control), pCI (negative control), and ten mutants. Cells were fixed with 4% PFA, stained with Hoechst (red) 
and probed with 1:400 4G2/Alexa 488 (green) and 1:500 Cholera Tx-B (blue). Mutants showed good 
expression levels compared to wt prME except for F422A, which showed no perinuclear binding. Cholera 
Tx-B showed inconsistent staining, possibly due to the age of this dye. 
 
Transfection of PS-EK cells (permeabilised), probed with Cholera toxin 
PS-EK cells were then transfected, permeabilised and probed with 4G2/488 (1:400), 
Hoechst (1:20,000) and Cholera Tx-B (1:500, 0.5 µg/µl solution) (figure 38). Again, 
positive fluorescence was high for wild-type prME and all ten MPER E mutants with 
F422A the exception. For F422A, there are negligible, background patches of 
fluorescence. Cholera Tx-B staining was seen in certain images (Y444A) was variable 
probably due to precipitation of the reagent as discussed previously. From the 
permeabilised and non-permeabilised data, a summary of expression and transfection 
efficiency averages was determined (table 9). For permeabilised cells, prME showed 
59% cells fluorescing while mutants ranged from 34 to 57% with outlying F422A at 8%. 
For non-permeabilised cells, prME showed 52% cells fluorescing, while mutants ranged 
from 24 to 43%. F422A again stood out from the other mutants, showing no perinuclear 
binding. It appears that this mutant, which lies in the conserved sequence (CS) just 
upstream from E2, does not display the epitope for 4G2 as well as the other mutants or it 
is not being expressed at the same quantity to allow for similar detection. 
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Figure 38.  Immunofluorescent confocal microscopy of PS-EK cells transfected with wt prME (positive 
control), pCI (negative control), and ten mutants. Cells were fixed with 4% PFA, stained with 1:20,000 
Hoechst (in red), 1:500 Cholera Tx-B (in blue) and probed with 1:400 4G2/Alexa Fluor 488 (green). Mutants 
showed good expression levels compared to wild-type prME except, again, with F422A. 
F448A F448Y 
20 µm 20 µm 
20 µm 20 µm 
Y444A Y444F 
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Permeabilised PS-EK cells: 4G2, Cholera Tx-B and Hoechst 
Plasmid Avg % of cells, 4G2/Alexa binding Expression Levels 
prME 59% High and even expression of E 
pCI 0% Negative control 
F422A 8% Low expression 
F422Y 54% High and even expression 
F429A 44% Moderate but variable expression 
F429Y 56% High expression 
F440A 53% High expression 
F440Y 44% Moderate expression 
Y444A 42% Moderate expression 
Y444F 48% High but variable expression 
F448A 57% High expression 
F448Y 34% Moderate expression 
 
Non-Permeabilised PS-EK cells: 4G2, Cholera Tx-B and Hoechst 
Plasmid Avg % of cells, 4G2/Alexa binding Expression levels 
prME 52% High expression of E  
pCI 0% Negative control 
 
F422A 27% Moderate expression, no perinuclear 
F422Y 29% Moderate expression 
F429A 38% High expression 
F429Y 24% Moderate expression 
F440A 36% Moderate expression 
F440Y 41% High expression 
Y444A 42% High expression 
Y444F 37% High expression 
F448A 38% High expression 
F448Y 43% High expression 
 
Table 9.  Fluorescence levels of transfected PS-EK cells. Immunofluorescent confocal microscopy 
of cells transfected with wt prME (positive control), pCI (negative control), and ten mutants. Expression 
levels of E is summarized. For permeabilised cells, prME showed 59% cells fluorescing while mutants 
ranged from 34 to 57% with outlying F422A at 8%. For non-permeabilised cells, prME showed 52% cells 
fluorescing, while mutants ranged from 24 to 43%. F422A again stood out from the other mutants, showing 
no perinuclear binding. 
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Transfection of PS-EK cells (non-permeabilised), probed with α-E 4G2 or 3H5 
To test antibody ∝-E 3H5 (domain I and III linker) in conjunction with antibody 4G2 
(fusion peptide), PS-EK cells were probed with 4G2 or 3H5 in parallel. This was to 
compare a 1:400 dilution of 3H5 with 4G2 in non-permeabilised, transfected cells (seen 
in figure 36). There was no staining with pCI, and prME showed approximately 30-40% 
transfection efficiency with either probe (figure 39). All ten mutants were probed with 
both antibodies but only a subset is shown (F448A and F448Y). These mutants, 
including F422A, showed consistent binding when comparing 4G2 with 3H5, displaying 
approximately even fluorescence with both antibodies.  
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Figure 39.  Immunofluorescent confocal microscopy of PS-EK cells transfected with wt prME (positive 
control), pCI (negative control), and ten mutants. Cells were fixed with 4% PFA, stained with 1:20,000 
Hoechst (in red) and probed 4G2 or 3H5 (1:400) and 1:400 Alexa Fluor 488 (in green). Mutants showed 
good expression levels, comparable to wild-type prME (not all mutants are shown). 
 
Transfection of cells with or without permeabilisation, probed with WGA  
After experimentation with molecular dyes (section 5.5) to track the progression of E 
through the secretory pathway, WGA (Wheat germ agglutinin) was determined to be the 
best dye to visualise other cellular organelles. It clearly stains the plasma membrane (for 
cell surface localisation), whilst also partially staining intracellular membranes as it binds 
with the Golgi apparatus. PS-EK cells were transfected and probed with 4G2, Alexa 
Fluor 488 (both 1:400), Hoechst (1:10,000), and WGA (1:500). Images shown display 
the Hoechst signal only (blue, upper left), Alexa/4G2 signal only (green, upper right), 
WGA only (purple, lower left) and merged (lower right, figure 40). As before, all ten 
mutants showed fluorescence comparable to wild-type prME upon probing with 4G2. 
F448A – 4G2 F448A – 3H5 
F448Y – 4G2 F448Y – 3H5 
20 µm 20 µm 
20 µm 20 µm 
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F422A was again the exception; non-permeabilised cell binding was in line with other 
mutants but upon permeabilisation, this mutant showed reduced levels of fluorescence in 
comparison. WGA stained plasma membranes well (PM, in purple), with most 
membranes evenly fluorescing. E protein is seen aggregating around the cellular 
surface, possibly favouring E binding receptors. With permeabilisation, a high degree of 
accumulation of E can be seen in the perinuclear region and diffused throughout the 
cytoplasm and secretory pathway (Golgi to ER) towards the PM. 
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non-permeabilised    permeabilised 
  
 
Figure 40.  Confocal microscopy of PS-EK cells probed with 4G2 and WGA. Images of PS-EK cells 
transfected with wild-type prME, negative control pCI and all ten E2 mutants. Cells were fixed or fixed and 
permeabilised, then probed with 4G2 (1:400), Alexa Fluor 488 (1:400, in green), Hoechst (1:10,000, in blue) 
and WGA (1:500, in purple). The WGA for pCI is in red due to a different imaging software. All E2 mutants 
showed decent levels of E protein expression compared to wild-type prME except for F422A, which was 
detectable but low. 
  
5.4.2. Analysis of cellular and surface expressed prM and E in infected 
cells 
To correlate E expression in transfected cells with that of infected, cells were infected 
with New Guinea C strain of dengue subtype 2 (NGC DENV-2). Twenty-four hours post-
infection, cells were either fixed or fixed and permeabilised. As shown in the following 
figures, Vero cells were infected at m.o.i. = 0.1 and 1. Dilutions of 4G2 (1:200 and 1:400) 
and 1:400 Alexa Fluor 488 were tested with m.o.i. = 0.1 (figure 41, top). Cells showed 
infectivity of around 5%, which was too low for comparison. Either dilution of antibody 
provided adequate fluorescence. Cells were also infected with m.o.i. = 1, which showed 
75% infectivity and good fluorescence with 4G2 at both 1:200 and 1:400 (figure 41, 
bottom). M.o.i. = 1 and 4G2 dilution of 1:400 was used in proceeding experiments for an 
infection control. After optimisation with molecular probes (section 5.5), an infection time 
point series was carried out, which best shows the visualisation of E in infected cells 
(see page 98). 
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Figure 41.  Immunofluorescent confocal microscopy of infected Vero cells with nuclei stain Hoechst 
(1:20,000), monoclonal antibody α-E 4G2 at 1:200 and 1:400 dilutions and conjugate dye Alexa Fluor 488 at 
1:400. [Top] With m.o.i. = 0.1 only ~5% of cells are infected suggesting that this m.o.i. is too low.  
[Bottom] At m.o.i. = 1 and 1:200 dilution of 4G2, infectivity is clearly shown (left, approximately 75%). 
Adequate fluorescence was seen with the 1:400 dilution of 4G2 (right). 
 
5.5. Analysis of the secretory pathway of prM and E 
5.5.1. Tracking of the secretory pathway with molecular probes and 
antibodies 
As a possible way of assaying fusion of DENV infected cells and/or tracking the 
progression of E through its secretory pathway, several molecular probes were tested, 
which stain an assortment of organelles. The probes tested (Invitrogen) include CM DiI 
(PM), CMAC and Calcein (cytoplasm), ER Tracker (endoplasmic reticulum), and WGA 
(Golgi apparatus and PM). Antibodies α-E 4G2 and 3H5 conjugated with Alexa Fluor 
488 were used and cells were counterstained with Hoechst or propidium iodide (nuclei).  
Un-infected PS-EK cells were seeded in 24-well plate format on to coverslips. Cells were 
not infected. After overnight incubation, cells were stained separately with cytoplasmic 
dyes Calcein (and Hoechst) or CMAC (and propidium iodide) or the plasma membrane 
50 µm 
1:200 1:400 
50 µm 
50 µm 50 µm 
1:200 1:400 
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dye CM DiI (and Hoechst). Cells were incubated at thirty minutes at 37°C for Calcein and 
CMAC or fifteen minutes at 4°C incubation for CM DiI. The cells were then fixed, 
washed, dried and mounted on slides. This first experiment was designed to optimise 
staining with even coverage on uninfected cells. CMAC was tested in 2.5-fold dilutions 
from 10 µM to 0.10 µM. Calcein was titrated in two-fold dilutions from 10 to 0.31 µM and 
CM Dil was tested in two-fold dilutions from 2.5 to 0.08 µM (optimal concentration 
shown, figure 43). Hoechst was diluted to 0.05 ng/ml and propidium iodide (CMAC only) 
was used at 10 mg/ml. The optimal concentration for Calcein was 2.5 µM, CMAC at 0.64 
µM, and CM DiI at 0.63 µM (figure 42 and 43).  
 
  
 
Figure 42.  Immunofluorescent confocal microscopy of PS-EK cells stained with CMAC and Calcein. 
[Left] PS-EK cells stained with CMAC (green) at 0.64 µM and Propidium Iodide (blue) at 10 mg/ml. These 
concentrations show even distribution of the cytoplasmic dyes. [Right] Immunofluorescent confocal 
microscopy of PS-EK cells stained with Calcein at 2.5 µM (red) and Hoechst at 0.05 ng/ml (blue). 
 
20 µm 10 µm 
CMAC 0.64 µM Calcein 2.5 µM 
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Figure 43.   Confocal microscopy of PS-EK cells stained with CM Dil and Hoechst. Non-infected PS-EK 
cells were stained with CM DiI (red) at 0.63 µM and Hoechst (blue) at 0.05 ng/ml. 
 
An endoplasmic reticulum dye (ER-Tracker) and a Golgi apparatus dye (WGA, wheat 
germ agglutinin), along with CM DiI and Hoechst were optimised. On fixed and 
permeabilised or non-permeabilised PS-EK cells, WGA was titrated from 10 µg/ml to 1 
µg/ml from a stock concentration of 5 mg/ml; 5 µg/ml appeared to be the best as 10 
µg/ml over-stained the cells and 1 µg/ml was not homogenous (optimal concentration 
shown, figure 44). WGA also appears to stain the PM, which would negate the need for 
a separate dye, and it distinctly stains the Golgi as seen in permeablised cells. 
 
non-permeabilised   permeabilised 
   
 
Figure 44.  Immunofluorescent confocal microscopy of non-infected PS-EK cells treated with WGA. 
WGA was titrated from 10 µg/ml to 1 µg/ml from a 5 mg/ml stock. 5 µg/ml appeared to be the best 
concentration as 10 µg/ml over-stained and 1 µg/ml was not homogenous. Golgi staining was consistent and 
plasma membrane shows clearly as well.  
 
 
CM Dil 0.63 µM 
10 µm 
WGA 1:500 
5 µg/ml 
20 µm 20 µm 
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ER Tracker, which stains the endoplasmic reticulum, was titrated from 250 nM to 1 µM. 
CM Dil was also titrated again from 0.63 µM to 2.5 µM on permeabilised and non-
permeabilised cells. Both of these dyes must be applied prior to fixation. The best 
concentration for ER Tracker was 1 µM (figure 45). ER Tracker cannot be used in 
conjunction with Hoechst as they both emit at the same wavelength. At 1 µM ER 
Tracker, some nuclei are also stained, which is not ideal. CM DiI, at 2.5 µM, proved 
more consistent at plasma membrane staining when heating this dye up before dilution. 
CM DiI also stains the cytoplasm along with the PM when cells are permeabilised. This 
may interfere when visualising the progression of E protein throughout the secretory 
pathway. 
 
 
non-permeabilised            permeabilised 
  
 
Figure 45.  Immunofluorescent confocal microscopy of non-infected PS-EK cells. [Top] ER Tracker 
was titrated from 250 nM to 1 µM with 1 µM the best concentration. The endoplasmic reticulum is seen 
distinctly although some nuclei are also stained. [Bottom] CM DiI was heated before dilutions, with the 
optimal concentration at 2.5 µM. Once cells are permeabilised, CM DiI displays the cytoplasm as well as the 
plasma membrane. 
ER-Tracker 
1 µM 
20 µm 
20 µm 20 µm 
CM-Dil 
2.5 µM 
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Ideally, to track the progression of E protein, CM DiI (PM) with Hoechst (nuclei) or WGA 
(Golgi and PM) with Hoechst would sufficiently display the relevant organelles. ER 
Tracker (ER) with propidium iodide (nuclei) could also be used. Because of the possible 
confusion of cytoplasmic staining with CM DiI upon permeabilisation, WGA with Hoechst 
seems most ideal in conjunction with α-E 4G2 and Alexa Fluor 488. Unfortunately, there 
is no molecular dye for endosomes. There are rabbit polyclonal antibodies available for 
Rab 5 (early endosome) and Rab 7 (late endosome). 
 
5.5.2. Tracking of the secretory pathway with molecular probes and 
antibodies in infected cells 
Continued testing of molecular probes was carried out with infected PS-EK cells and the 
following optimized dyes: ER Tracker (endoplasmic reticulum), WGA (Golgi apparatus) 
and CM DiI (PM). These dyes were used on their own or in combination with Hoechst 
and 4G2 (α-E fusion peptide antibody) in conjunction with Alexa Fluor 488.  
PS-EK cells were infected at m.o.i. = 2 for 24 hours and either fixed or fixed and 
permeabilised. The optimised concentration from previous experiments of WGA was 10 
µg/ml, CM DiI was 2.5 µM and ER Tracker was 1 µM. It is recommended that ER 
Tracker be used prior to fixation, as is CM DiI. WGA may be used either before or after. 
On fixed and infected cells, all three dyes were tested to determine if the PM and ER 
could be stained post-fixation. E monoclonal antibody 4G2/488 was tested in 
combination with the organelle dyes.  
ER Tracker stains the endoplasmic reticulum well and can be used post-fixation but it is 
not distinguishable from Hoechst as they both emit at the same frequency (figure 46). 
WGA clearly displays the Golgi apparatus and PM in combination with 4G2/488. CM DiI 
should not be used prior to fixation, as it does not stain the PM well (data not shown). 
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Figure 46.  Immunofluorescent confocal microscopy of infected PS-EK cells. Cells are probed with 
4G2 and Alexa Fluor 488. [Top] ER Tracker stains the ER clearly but it emits at the same wavelength as 
Hoechst (both in red). [Bottom] WGA, shown without Hoechst, clearly displays the Golgi and plasma 
membrane. 
 
ER Tracker, CM Dil, and WGA were then tested in combination on infected PS-EK cells 
and applied prior to or post-fixation as recommended. PS-EK cells were infected for 24 
hours at m.o.i. = 2. CM DiI (applied after fixation) with 4G2 and Hoechst on non-
permeabilised cells stained the PM (blue) and E protein was clearly seen (green, figure 
47). CM DiI with ER Tracker and 4G2 applied before fixation with permeabilisation did 
not work. It is not clear whether this is due to application of the two dyes or that CM DiI 
does not intercolate well prior to fixation. 
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No Hoechst 
ER Tracker 
Hoechst 
WGA 
No Hoechst 
20 µm 
20 µm 
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                     Non-Permeabilised, Treated After Fix            Permeabilised, Treated Before Fix 
  
 
Figure 47.  Immunofluorescent confocal microscopy images of infected PS-EK cells, permeabilised or 
non-permeabilised. Cells were stained with CM DiI (plasma membrane, blue), 4G2/488 (green) and Hoechst 
(nuclei, red), with or without ER Tracker (endoplasmic reticulum, red). CM DiI stains well with infected cells 
treated post-fixation. In combination with ER Tracker, the dyes were unclear but this may be due to the 
application of CM DiI requiring fixation as recommended or the two dyes interfering when applied together. 
 
WGA with 4G2/488 and Hoechst on non-permeabilised cells stained well, clearly 
displaying the PM (blue, figure 48). Cell surface expression of the protein E in green is 
seen clearly. With permeabilised cells, the Golgi apparatus can be seen but it is more 
difficult to see the plasma membrane; E expression throughout the cytoplasm is well 
visualised. This dye works wells prior to fixation with permeablisation or without. 
 
Non- Permeabilised, After Fixation  Permeabilised, After Fixation 
  
 
Figure 48.   Immunofluorescent confocal microscopy images of infected PS-EK cells, permeabilised or 
impermeabilised. Cells were stained with WGA (Golgi apparatus, blue), Hoechst (nuclei, red) and α-E 4G2 
with Alexa Fluor 488 (green).  
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WGA with ER Tracker and 4G2/488 on non-permeabilised cells (before fixation) shows a 
well-detailed view of the plasma membrane and E expression (figure 49, top left). Not 
seen previously, E is shown expelled from the cell surface. With permeabilisation, ER 
can be seen relatively well (red) and the PM in blue (WGA). WGA with ER Tracker and 
4G2 on permeabilised cells (after fixation) shows a lot of overlapping with the dyes 
(figure 49, bottom), which deems the combination of dyes not useful. 
 
 Non-Permeabilised, Treated Before Fixation      Permeabilised, Treated Before Fixation 
  
 
Permeabilised, Treated After Fixation 
 
 
Figure 49.  Immunofluorescent confocal microscopy images of infected PS-EK cells, permeabilised or 
non-permeabilised. [Top] Cells were stained with WGA (Golgi apparatus and PM, blue), α-E 4G2 with Alexa 
Fluor 488 (green) and ER Tracker (red). E protein is clearly detected on the cell surface, the PM is stained 
well with WGA and the nuclei and ER is stained well with ER Tracker. The arrow shows E protein being 
expelled from the cell. [Bottom] Permeabilised cells were stained with WGA (blue), 4G2 with Alexa Fluor 
488 (green) and ER Tracker (red). E protein is clearly detected in the cytoplasm but the nuclei, ER and Golgi 
staining overlap too much. 
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ER Tracker 
WGA 
ER Tracker 
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In summary, these dyes display organelles well in the presence of α-E antibody 4G2 
staining with or without Hoechst. ER Tracker works well with WGA on non-permeabilised 
cells whereas when the cells are permeabilised, the plasma membrane staining is lost. 
CM DiI works well with Hoechst but possibly not with ER; this dual stain should be 
repeated to confirm results. It is better to use CM DiI before cell fixation but ER Tracker 
and WGA can be used before or after. It would be beneficial to acquire an endosomal 
dye to complete the E secretory pathway but a single organelle dye is not available. 
There are rabbit polyclonal antibodies available for Rab 5 (early endosome) and Rab 7 
(late endosome). If recombinant infectious particles with wild-type prME and the 
individual MPER α-helix E2 mutations are made successfully, this system would be 
useful in tracking DENV E throughout the secretory pathway. In conclusion, these 
molecular probe experiments showed that the best combination is WGA in conjunction 
with 4G2 and Alexa Fluor 488 (table 10). 
 
 Organelle Optimal Combinations 
Hoechst Nuclei  
Propidium Iodide Nuclei  
Cholera Tx-B Lipid Rafts/Plasma Membrane Combine with Hoechst 
Calcein Cytoplasm  
CMAC Cytoplasm  
CM Dil Plasma Membrane Combine with Hoechst 
ER-Tracker Endoplasmic Reticulum Combine with WGA 
WGA Golgi (and Plasma Membrane) Combine with ER-Tracker or Hoechst 
 
Table 10. Cellular dyes: target organelle and optimal combinations. In PS-EK cells, these molecular 
probes target particular cellular components. The optimal combinations targeting multiple organelles, along 
with 4G2/488, are shown.  
 
5.5.3. Localisation of E in infected cells 
Organelle dyes were finally tested on infected PS-EK cells in a time point series with the 
following dyes: ER Tracker (endoplasmic reticulum), WGA (Golgi apparatus), CM DiI 
(PM), Hoechst (nuclei), and 4G2 (α-E fusion peptide) in conjunction with Alexa Fluor 
488. Previously optimised concentrations of ER Tracker (1 µM), WGA (10 µg/ml) and 
CM DiI (2.5 µM) were used. PS-EK cells were infected at m.o.i. = 2 and cells fixed at 
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time points 4, 8, 12, 14, 16 and 24 hours. Some samples were also permeabilised. The 
best image for each time point is shown (figures 50-53). 
In figure 50, CM Dil and Hoechst was used on non-permeabilised PS-EK cells. At 4 
hours, E protein can be seen just after translation. It appears to be expressed and 
migrating to the cell surface by 8 hours. At 16 hours, the arrow shown depicts the 
accumulation of E at the cell surface. E can be seen extending out from the plasma 
membrane. In figure 51, WGA and Hoechst stains permeabilised PS-EK cells. At 8 
hours, there is some E protein visible outside the nucleus. There are large amounts of E 
being expressed and migrating through the secretory pathway at 12 hours. This 
increases at 14 and 16 hours. At 24 hours, E is seen aggregating at the plasma 
membrane. In figure 52, WGA, ER-Tracker and Hoechst, in combination, is used on non-
permeabilised PS-EK cells. At 8 hours, E protein can just be seen after translation. By 
time point 14 hours, E protein is shown at the perimeter of the cells. There are large 
amounts of E being generated in the endoplasmic reticulum at 16 hours. E has migrated 
through the trans-Golgi network to the cell surface by 24 hours. The plasma membrane 
is well visualised with WGA but the ER-Tracker dye is difficult to see as it is in the same 
spectrum as Hoechst. In figure 53, the same combination of dyes (WGA, ER-Tracker, 
and Hoechst) is used on permeabilised PS-EK cells. There is some E protein visible at 4 
hours, seen as punctation on the cellular surface. This could be incoming viral particles, 
which had not been seen previously. At 8 hours, E is visible in the cytoplasm and at 12, 
it appears E is being translated in the ER. There are large amounts of expression and 
migration through the secretary pathway at 14 hours, which increases at 16 and 24 
hours. 
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CM DiI, Hoechst with non-permeabilised cells    
  
 
 
 
  
 
 
Figure 50.  Immunofluorescent confocal microscopy images of infected PS-EK cells non-
permeabilised and probed with 4G2/488 (green). Cells are stained with CM DiI (blue, PM) and Hoechst 
(red). The arrow depicts the accumulation of E at the cell surface and extending out from the plasma 
membrane. 
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WGA, Hoechst with permeabilised cells    
  
 
 
 
 
 
 
Figure 51.  Immunofluorescent confocal microscopy images of infected PS-EK cells permeabilised 
and probed with 4G2/488 (green). Cells are stained with WGA (blue) and Hoechst (red). The arrow, at 8 
hours, shows E after translation around the nuclei. At 24 hours, E is seen aggregating at the cell surface 
(arrow). 
20 µm 
24 hr 16 hr 
14 hr 12 hr 
8 hr 4 hr 
 103 
WGA, ER-Tracker, Hoechst with non-permeabilised cells  
  
 
 
 
 
 
 
Figure 52.  Immunofluorescent confocal microscopy images of infected PS-EK cells non-
permeabilised and probed with 4G2/488 (green). Cells are stained with WGA (blue), ER-Tracker (red) and 
Hoechst (also in red). The arrows depict the migration of E to the cell surface at 14 hours and extending 
from the PM at 24 hours. 
20 µm 
8 hr 4 hr 
12 hr 14 hr 
24 hr 16 hr 
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WGA, ER Tracker, Hoechst with permeabilised cells 
  
 
 
 
 
 
 
Figure 53.  Immunofluorescent confocal microscopy images of infected PS-EK cells permeabilised 
and probed with 4G2/488 (green). Cells are stained with WGA (blue), ER-Tracker (red) and Hoechst (also in 
red). The arrow depicts E protein at the cell surface at 4 hours, which could be incoming viral particles. 
20 m 
24 hr 16 hr 
12 hr 14 hr 
8 hr 4 hr 
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To summarize this time point series, with permeabilised cells (WGA, ER-Tracker, and 
Hoechst images, figures 51 and 53), E can be seen at 4 hours, which could be incoming 
viral particles. After receptor-mediated endocytosis, fusion and release from endosomes, 
cytoplasmic E appears at 8 hours. Post-synthesis, E can be found in the ER/Golgi 
apparatus at 12-14 hours. With non-permeabilised cells, E appears at the cell surface by 
12-14 hours (CM DiI and Hoechst, figure 50 and WGA, ER-Tracker, and Hoechst, figure 
52). Accumulation of translated E protein appears at 14-16 hours. Cell surface 
appearance and exocytosis occurs at 16-24 hours. The pathway for E localisation, as 
described, is portrayed in the diagram below (figure 54). 
 
 
 
Figure 54.  Possible timepoints for the virus pathway [95]. The replication pathway starts with 
attachment and receptor-mediated endocytosis at 4 hours. Cytoplasmic E appears at 8 hours. After 
translation, endoplasmic reticulum and Golgi apparatus presence occurs at 12 to 14 hours. Release of viral 
particles occurs between 16 and 24 hours. 
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5.6. Discussion 
5.5.3. Conclusions of cellular and surface expressed MPER E2 mutant 
protein 
PS-EK cells were transfected and probed with α-E 4G2 (fusion peptide) or 3H5 (DI and 
DIII linker), 1:400 Alexa Fluor 488, Hoechst and tertiary dyes Cholera Tx-B (lipid rafts) or 
WGA (Golgi and plasma membrane staining). Transfection efficiencies were 92% as 
detected by 4G2 with wild-type prME and mutants ranging from 49 to 85%, in the 
absence of a tertiary dye. The number of cells expressing perinuclear staining of E 
protein was quantified. For wt prME this was 33%, while mutants ranged from 7 to 19%. 
Antibody 3H5 was tested in parallel with 4G2 and both showed similar fluorescence. 
Cholera toxin was tested to confirm homogenous fluorescence was background signal 
and not E expression. With Cholera Tx-B added and cells permeabilised, 59% of cells 
were positive for wt prME while mutants ranged from 34 to 57% with outlying F422A at 
8%, which agrees with immunoblot conclusions. For non-permeabilised cells, 52% of 
cells were positive for wt prME, while mutants ranged from 24 to 43%. F422A again was 
in contrast to the other mutants, showing no perinuclear localisation. In transfected cells 
stained with WGA and Hoechst, F422A was also the exception; non-permeabilised cell 
binding was comparable to other mutants but upon permeabilisation, this mutant showed 
reduced levels of fluorescence. The F422A mutation is just upstream to the conserved 
sequence (CS) between ∝-helix E1 and E2. The F422A mutants that are cell-surface 
expressed must be in a favourable conformation for 4G2 binding, in contrast to protein in 
the cytoplasm. Or alternatively, the binding site for 4G2 may be lost in its tertiary 
conformation as it is adjacent to the CS. With all other mutants, E protein is seen clearly 
in the perinuclear region and throughout the secretory pathway (Golgi to ER) en route to 
the PM. 
Several molecular probes were tested, which include CM DiI (PM), Cholera Tx-B, CMAC 
and Calcein (cytoplasm), ER Tracker (endoplasmic reticulum), and WGA (Golgi 
apparatus and PM), along with α-E 4G2 and 3H5 conjugated with Alexa Fluor 488. Cells 
were counterstained with Hoechst or propidium iodide (nuclei). The optimal 
concentration for Calcein was 2.5 µM, CMAC at 0.64 µM and CM DiI at 0.63 µM. CM DiI, 
Hoechst and 4G2/488 can be used together to visualise the plasma membrane and E 
expression in infected PS-EK cells. CM DiI also stains the cytoplasm with permeabilised 
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cells, which can interfere with tracking E, while CMAC can be used to stain the 
cytoplasm with 4G2/488 and without Hoechst. The best concentration for WGA was 5 
µg/ml and whilst it stains the Golgi it also stains the PM, which would negate the need 
for a separate dye. Cholera Tx-B was tested to display lipid rafts and its optimal 
concentration appeared to be 1:500 although this dye was precipitating. CM DiI (PM) 
was titrated from 0.63 µM to 2.5 µM along with ER Tracker (ER) from 250 nM to 1 uM. 
The best concentration for this combination was 2.5 µM for CM DiI and 1 µM for ER 
Tracker. Interference occurs with CM DiI staining both the cytoplasm and PM when 
permeabilised and ER Tracker cannot be used with Hoechst as they both emit at the 
same wavelength. 
Ideally, to track the progression of E protein, CM DiI (PM) with Hoechst (nuclei) or WGA 
(Golgi and PM) with Hoechst would sufficiently identify the relevant organelles. ER 
Tracker (ER) with propidium iodide (nuclei) could also be used. Because of the possible 
confusion of cytoplasmic staining with CM DiI upon permeabilisation, WGA with Hoechst 
seems most ideal in conjunction with α-E 4G2 or 3H5 and Alexa Fluor 488. It is the most 
useful tertiary dye as it stains both the Golgi apparatus and the plasma membrane.  
PS-EK cells were infected with DENV-2 and probed with 4G2 and Alexa Fluor 488 at a 
1:400 optimal dilution. The cells were stained at various time points with the following 
dyes: ER Tracker, WGA, CM DiI, Hoechst, and 4G2/488. Cells were infected at m.o.i. = 
2 and fixed at time points 4, 8, 12, 14, 16 and 24 hours. Upon permeabilisation, E is 
seen as incoming viral particles at the cell surface at four hours. After translation, E 
appears in the cytoplasm at eight hours, followed by ER/Golgi apparatus presence at 
twelve to fourteen hours post-polyprotein processing. Without permeabilisation, 
accumulation of translated E protein appears at fourteen to sixteen hours. This is 
followed by PM appearance and exocytosis at sixteen to twenty-four hours (table 11). To 
see E internally, cells should be fixed at fourteen and sixteen hours (permeabilised and 
non-permeabilised, respectively). To track E to the cell surface, cells should be fixed at a 
minimum of sixteen hours. 
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Dye Compartment Labeled Co-Localisation with E 
(Hours) 
  4 8 12-14 14-16 24 
WGA, CM Dil Plasma Membrane 
(Endocytosis) 
+ + - - - 
ER-Tracker, 
WGA 
ER and Golgi 
Apparatus 
- + + + + 
WGA, CM Dil Cytoplasm and 
Cellular Surface 
+ + + + + 
WGA, CM Dil Plasma Membrane 
(Exocytosis) 
- - - + + 
 
Table 11. Localisation of E with 4G2/488 and cellular dyes. In combination with α-E 4G2/488, these 
molecular probes are the best choice to visualise listed organelles. 
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CHAPTER 6 
RESULTS: INSECT CELL LINE EXPRESSION OF prM AND E 
6.1. Introduction and design of pSFV-prME vector   
To compare the results of MPER E2 mutant expression in a mammalian cell line with 
insect-derived E protein, a plasmid was created to transfect C6/36 cells. A cassette 
system was developed to insert wild-type and mutant prME segments into a second 
vector, pSFV (Semliki Forest Virus replicon) for insect cell expression. pSFV (Invitrogen) 
is a cDNA clone containing non-structural proteins, 26S subgenomic RNA promoter, 5’ 
and 3’ UTRs, ampicillin resistance and MCS (figure 20). The plasmid pSFV was stripped 
of all but the AmpR gene and MCS sequences and these were ligated to a linker 
containing unique restriction sites for cloning. This linker contains the sites Not I and Xho 
I, allowing for insertion of the prME gene. This ligation generates the pSFVprME 
“cassette” vector, which is 5.2 kB in length (figure 55). This vector, along with wt pSFV 
was then digested with Spe I and BamH I, which produced two products, a 10172 bp 
product from pSFV and a 2917 bp product from the pSFVprMEcassette. These products 
were then ligated together to make a 13 kB full-length pSFVprME clone. Purified plasmid 
was transformed into competent cells. Figure 56 shows twenty-four of these 
transformants, one of which was the correct length.  
 
 
 
Figure 55.  Agarose gel of pSFV cloning products. Lane 1 is wt pSFV followed by pSFVprMEcassette 
(cass), pSFV digested with Spe I and BamH I, and pSFVprMEcassette digested with Spe I and BamH I. 
pSFVprME cassette is 5.2 kB in length and cut with these two enzymes results in two bands, 2342 and 2917 
bp in length. Wild type pSFV cut results in 861 and 10172 bp bands. The 10172 bp band ligated to the 2917 
bp of pSFVprMEcassette (arrows point bands) results in the new 13 kB pSFVprME vector. 
 
10172 bp 
2917 bp 
pSFV    cass 
  
   
pSFV    cass 
   digested 
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Figure 56.  Agarose gel of transformants from the ligation of wt pSFV and pSFVprMEcassette (Spe I 
and BamH I). There are twenty-four transformants shown (Samples 37-60) and Clone 48 is positive for the 
correct length of 13 kB (circled). This pSFVprME (wild-type) plasmid will be used as the control against 
mutant pSFVprME plasmids. 
 
Four of these transformants were digested with EcoR I, which cuts at several sites 
(figure 57). The correct 13 kB plasmid will be cut at bases 2185, 3763, 7390, 7411 
resulting in 1578, 3627, 21 and 7861 bp bands. In contrast wt pSFV has three cut sites 
at bases 2185, 3763, 7390 resulting in 1578, 3627 and 5828 bp bands and 
pSFVprMEcassette has one at base 3214, which linearises the plasmid. Wild-type prME 
also only has one site, which linearises the plasmid to 7485 bp. Clone 48 resulted in the 
correct-sized bands; it was subsequently sequenced and shown to be correct.  
 
 
 
Figure 57.  Agarose gel of pSFVprME clones 37, 38, 48 and 49 diagnostic digest. Clones were 
digested with EcoR I to test correct restriction enzyme cut sites. The correct 13 kB plasmid cuts at 2185, 
3763, 7390, 7411 resulting in 1578, 3627, 21 and 7861 bands (the 21 bp band is not visible). Clone 48 was 
subsequently sequenced and shown to be the correct plasmid (boxed). 
 
Lane Sample   Results 
1 Clone 37 Eco Linearised to 7485 (prME wt) 
2 Clone 38 Eco Linearised to 3214 (pSFVprMEcassette) 
3 Clone 48 Eco Possible positive for pSFVprME – 7861, 3627, 1578 
4 Clone 49 Eco Linearised to 3214 (pSFVprMEcassette) 
 
The pSFVprMEcassette vector was then used as the backbone for cloning all ten MPER 
E2 mutations. pCI_NGCprME mutants were digested with Not I and Xho I and the band 
37            40                 44                 48                 52                 56                 60 
10 kB 
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  6 kB 
Clone 48 
     1        2          3         4 
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containing prME was excised and purified from agarose (figure 58). This was then 
ligated with pSFV (Not I/Xho I) to create pSFVprMEcassette mutant plasmids. After 
transformation, several clones were again digested with Not I and Xho I to select for 
correct-sized bands. Three of these mutants (F429A, F448A, and Y444A) that had the 
correct-sized bands are shown in figure 59. All ten cassette vectors were made and 
confirmed by diagnostic restriction digests. It was intended that these cassette mutants 
would be then digested to clone mutant prME back into full-length pSFV, however due to 
time constraints this last cloning step was not completed. 
 
 
 
Figure 58.  Agarose gel of pCI_NGCprME E2 mutants. Plasmids were digested with Not I and Xho I to 
obtain the 2917 bp prME mutant segment. Samples are as follows: F422A, F422Y, F429A, F429Y, F440A, 
F440Y, Y444A, Y444F, F448A, F448Y uncut (U) followed by digested plasmid (C). The bottom bands were 
gel extracted and purified. These mutant prME segments were subsequently ligated with digested 
pSFVprME cassette (Not I/Xho I). Ligations were transformed into Top ten cells and tested for presence of 
prME insertion by diagnostic colony PCR. 
 
 
 
 
Figure 59.  Agarose gel of possible pSFVprMEcassette mutant clones. Plasmids were digested with 
Not I and Xho I to diagnose presence of the prME E2 mutant gene. The first set of samples numbered 7-12, 
are F448A, the second F429A and the third, Y444A. The correct sized plasmid should be 5.2 kB, which 
when cut with Not I and Xho I results in two bands 3.2 and 2 kB. Clones F448A 8 and 10, F429A 9, 10 and 
11, and Y444A 9, 11 and 12 had the correct sized digestion products. This is an example of selection of 
pSFVprMEcassette mutant plasmids; the other mutants are not shown. 
F422A   F422Y   F429A   F429Y   F440A   F440Y   Y444A   Y444F   F448A   F448Y 
 U   C      U   C     U    C     U   C     U   C      U    C     U    C    U    C      U   C     U   C 
10 kB 
 
 
6 kB 
10 kB 
 
 
6 kB 
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1 kB 
F448A  8        10             F429A  9   10  11        Y444A 9        11 12 
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6.2. Results: Transfection of wt pSFVprME with C6/36 cells to test expression 
of prM and E 
RNA was transcribed from the cloned wild-type pSFV-prME plasmid and appears to be 
expressing with a preliminary test of transfected C6/36 cells. Wild-type pSFV-prME was 
linearised, purified and transcribed with SP6 RNA polymerase according to the 
procedure described in Materials and Methods. C6/36 cells were transfected 
immediately following transcription, with 1.6, 3.2 and 6.4 µg of wt pSFV-prME RNA. Cells 
were fixed twenty-four hours post-transfection. Samples were then blocked and probed 
with 4G2/488 and Hoechst. Cells were visualised with confocal microscopy and positive 
fluorescence was seen (green, figure 60). The majority of cells appear to show 
expression of prME and protein can be seen throughout the cytoplasm. There is a small 
degree of background fluorescence with the mock-transfection (bottom left image) due to 
Alexa Fluor 488 at this concentration.  
   
   
Figure 60.  Test transfection with RNA pSFV-prME in C6/36 cells. [Top] Cells were probed with 1:400 
4G2/488 and 1:10,000 Hoechst. [Bottom] The left image is a mock transfection, which shows a small 
degree of background fluorescence with Alexa Flour 488. The right image is a control sample with cells 
infected with DENV-2. 
20 µm 20 µm 
 
20 µm 
 
20 µm 
 
3.2 ug RNA 6.4 ug RNA 
mock INF 
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6.3. Discussion 
6.3.1. Further work on expression of prM and E in C6/36 cells 
After all ten E2 mutant pSFVprME vectors are made, these plasmids would be 
transcribed and transfected into C6/36 cells. These cells would then be analysed 
similarly to mammalian cells, including expression of prME mutant protein, trafficking and 
maturation along the secretory pathway. Instead of analysis with FACS on RNA 
transfected C6/36 cells, in-cell analysis could be used to quantify cell surface and 
cytoplasmic expression (section 5.2.2.). FACS analysis provides inconsistent results with 
the conditions used in previous experiments with mammalian cell lines. In-cell analysis 
appeared promising and may be a more consistent detection method for quantifying 
expression of prME. It also has the advantage of assaying 384 samples at a time, in 
microtiter plates. SDS-PAGE and Western immunoblots should be completed to confirm 
protein expression of prME in C6/36 cells and E epitope display. Immunofluorescent 
confocal microscopy images should then be obtained to view prME secretory trafficking, 
cell surface and cytoplasmic expression, along with calculation of transfection 
efficiencies to compare with mammalian cells. Transfected C6/36 cells would be probed 
with 3H5 and 4G2 in combination with Hoechst and WGA. 
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CHAPTER 7 
GENERAL DISCUSSION      
The aim of this research project was to determine the structural significance of the 
membrane-proximal (MPER) E2 α-helix in Dengue’s E protein in pH-activated 
conformational change and its role in membrane fusion. To begin this structural analysis, 
single-point mutations (F422A/Y, F429A/Y, F440A/Y, Y444A/Y, F448A/Y) were inserted 
into ten separate NGC_prME_opt_neo plasmids, by site-directed mutagenesis. These 
amino acid mutants were then available to investigate the role of each of these residues 
in the structural changes of E, including prME heterodimeric formation and protein 
maturation. 
For the second aim of this project, a lentiviral system was developed to assay these 
mutations. Pseudotyped retroviral particles were constructed to provide a method of 
measuring fusion by successful entry of prME lentivirus into target cells. There are 
several challenges with this system. After transfection, cells must take up all four 
plasmids and expression must be sufficient for infectious particles to assemble. The 
harvested supernatant must be concentrated, providing sufficient virus for transduction. 
There was low efficiency of lentiviral particle formation with prME, subsequently leading 
to low rates of infection. This could be due to prME’s ER-retention signal and/or catalytic 
cleavage of prM. A long harvest is also necessary for an effective level of virus. To 
overcome these problems, it might be possible to design a three-plasmid, luciferase 
reporter system, similar to assays currently in use for HCV. This would result in a higher 
transfection efficiency with one less plasmid needing to be incorporated and thus, larger 
amounts of lentivirus generated [91]. These pseudotyped lentiviral particles could then 
be assayed using the sensitive luciferase detection system.  
The third aim of this project was to investigate the structural character of MPER E2 
mutants by localising E within the cell and cellular compartments in a mammalian cell 
line. To quantify cell surface expression, cells were transfected, fixed and probed with 
antibodies 3H5 (anti-E domain I and III linker) and 4G2 (anti-E fusion peptide) and 
analysed by flow cytometry. Preliminary results showed positive fluorescence but 
subsequent experiments showed variability, with a lack of sensitivity similar to the 
drawbacks of lentiviral pseudotype particle system. This method of quantification may 
have benefitted from harvesting cells at three days instead of one day post-transfection, 
as with lentivirus. There was a low level of E expressed at the surface, since it could be 
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detected in non-permeabilised cells. In contrast, in permeabilised cells, E levels were 
significantly higher. A longer harvest would allow for E to migrate to the cell surface, thus 
increasing surface expression.  
Western immunoblots were performed to confirm the expression and stability of mutant 
E proteins. This system was optimised for cell lysis (lytic buffer), immunoblot transfer 
(semi-dry and submerged), and antibody incubation (time and volume). 4G2 recognises 
the E2 mutants F429A, F440A, Y444A, F448A well but not F442A. An additional band 
appears above 65 kDa with the infected control and mutant F448A. This could be a 
difference in glycosylation of the envelope protein, causing a change in migration 
patterns. MPER E2 mutants F422Y, F429Y, F440Y, Y444F, and F448Y were all 
detected by 4G2 while F448Y migrated lower than wt prME but in line with the infected 
control sample. It is unclear whether or not this was gel artifact as F448Y was run next to 
the infected control. 3H5 recognised all alanine mutants, with F442A detected most 
readily by this antibody. There may be a conformational preference for the 3H5 epitope 
between DI and DIII, due to F422’s position between the E1 and E2 helices. E2 mutants 
F422Y, F429Y, F440Y, Y444F and F448Y were all recognised by 3H5.  
To track E progression through the secretory pathway, its cell-surface expression and to 
calculate transfection efficiencies, mammalian PS-EK cells were transfected and 
analysed by immunofluorescent confocal microscopy. Cells were probed with 4G2 or 
3H5 with Hoechst and tertiary dye WGA (Golgi/PM staining). With both antibodies, E 
protein localised into perinuclear foci, appearing throughout the cytoplasm and 
expressed on the cell surface. As with Western immunoblot data, F422A showed 
consistent differences, displaying low to no fluorescence when probed with 4G2 in 
permeabilised cells. In non-permeabilised cells, F422A showed reduced but comparable 
levels of fluorescence with the other mutants. The F422A mutation is just upstream from 
E2, within the conserved sequence between ∝-helix E1 and E2. It is possible that F422A 
mutants that are present on the cell surface are in a favourable conformation for 4G2 
binding, in contrast to protein within the cytoplasm.  
Several cellular dyes were optimised for concentration and incubation times, including 
CM DiI (PM), CMAC and Calcein (cytoplasm), ER Tracker (endoplasmic reticulum), and 
WGA (Golgi apparatus and PM) along with 4G2 and 3H5 antibodies. Cells were 
counterstained with Hoechst or propidium iodide (nuclei). While CM Dil and ER-Tracker 
were useful probes to track the progression of E, the combination of WGA and Hoechst 
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was the most suitable, in conjunction with 4G2 or 3H5, as it stains both the Golgi 
apparatus and the plasma membrane. There is a new pH-sensitive molecular dye 
available specifically for endocytosis called pHrodo™ (Molecular Probes) [96]. This dye 
is non-fluorescent at neutral pH and fluoresces bright red in acidic environments. The 
minimal dye fluorescence at neutral pH also eliminates the need for wash steps and 
quencher dyes, which reduces handling, timing, and loss of samples. It can also be 
multiplexed with other dyes such as eGFP, CM Dil, or WGA. This dye could be tested in 
conjunction with WGA, 4G2/488, and Hoechst to track fusion between E and the 
endosome/lysosome. 
PS-EK cells were also infected and probed with 4G2/488 and tested with cellular dyes in 
an infection time point series. CM DiI (PM) was tested on its own and WGA (Golgi 
apparatus/PM) was used with or without ER Tracker. Cells were infected at m.o.i. = 2 
and fixed at time points 4, 8, 12, 14, 16, and 24 hours. With permeabilised cells, E can 
be detected at four hours, seen as punctation on the cellular surface. This could be 
incoming viral particles undergoing receptor-mediated endocytosis. Cytoplasmic E 
appears at eight hours, which could be release of the nucelocapsid after low-pH 
lysosome fusion. After translation of prM and E, viral assembly begins in the ER and 
Golgi, seen at twelve to fourteen hours. With non-permeabilised cells, accumulation of 
translated E appears at the cell surface and exocytosis occurs at sixteen to twenty-four 
hours. To see internal E, cells should be fixed at fourteen and sixteen hours 
(permeabilised and non-permeabilised respectively). To track E expression to the cell 
surface, cells should be infected for a minimum of sixteen hours prior to fixing. 
It is now known that residues F422 and F448 do not lie strictly in the α-helix E2 but do 
correlate with the membrane-proximal external region (MPER). F422 is located in the 
conserved (CS) region between the two helices. F429 is in the α-helix E2, along with 
F440 and F444. F448 is part of the four amino acid C-terminus of E2 [97]. For DENV-2, 
the N-terminus of the stem region is thus G395-S397, α-helix E1 is I398-L415, the CS is 
G416-S424, α-helix E2 is L425-A447 and the C-terminus is F448-V491 [69, 70] (figure 
61).  
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Figure 61.  Diagram of Dengue MPER ∝-helices E1 and E2. [Top] Revised position of E1, CS, and 
E2 for DENV-2. The location of the five hydrophobic mutations are shown in blue. The location of F422 is in 
the CS region and not E2 while F448 is in the C-terminus. [Bottom] Multiple sequence alignment of JEV and 
DENV-1 through 4 showing the non-conservative residues (adapted from [97]). 
 
Previously, F429 has been proven to be crucial in the formation of virus-like particles 
(VLPs), heterodimerisation and protein production [68]. When mutated to proline (to 
disrupt the ∝-helix) in a pSFV system, a lower rate of infectivity occurred, as well as low 
levels of protein expression and viral RNA production. With this mammalian system, 
F429A does not show reduced protein expression as seen with the Western immunoblot 
data and confocal immunofluorescent images of transfected PS-EK cells. F422 has also 
been mutated to proline, resulting in reduced viral assembly and membrane binding [68]. 
With F422 substituted for alanine in this series of mutations, epitope binding to 4G2 was 
unsuccessful. Expression of prME, as assessed by immunofluorescence imaging, was 
reduced but trafficking and localisation to the cytoplasm was detected. Since F448 
resides outside the E2 ∝-helix, it is unlikely to disrupt conformation while the removal of 
side groups for F440A and Y444A mutations may not interfere with helix formation. It is 
likely that F429Y, F440Y, and Y444F are helix-retaining conservative mutations.  
To properly view fusion and syncticial formation, mutants should be tested within an 
insect system in contrast with this mammalian system. Infection with dengue in 
mammalian cell lines does not produce multi-nucleated cells, while in A. albopictus cell 
lines, it is well-demonstrated [98, 99]. In C6/36 cell lines, fusion can be seen with high 
m.o.i. [100] or with low-pH culture media [101]. To complete the structural analysis of all 
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ten MPER ∝-helix E2 mutants, these mutations were introduced into a pSFV vector for 
transfection into C6/36 cells. The wild-type prME clone was transfected by in vitro 
transcription of RNA under the control of the pSFV vector. PrME expression was clearly 
detected. Eight of the MPER ∝-helix E2 mutants (discarding F448A/Y) need to be cloned 
into the full-length pSFV vector and transcribed. For comparative analysis, SDS-PAGE 
and Western immunoblots with expressed wt prME and mutant proteins should be run 
with standardized quantities. In-cell analysis with transfected C6/36 cells should be 
completed to quantify cell surface and cytoplasmic expression. Mutants would be 
imaged with immunofluorescent confocal microscopy to confirm protein expression, 
localisation of E and cell surface trafficking. Cells should be probed with Hoechst, WGA 
and 4G2/488. The molecular dye for endocytosis, pHrodo™, could also be tested. 
Transfection efficiencies should be calculated to compare with mammalian cells. And 
finally, these mutants could be tested in a C6/36-based fusion assay. A functional 
syncytial assay has previously been developed in the Young laboratory (J. Robinson, P. 
Campbell) to analyse recombinant prM and E proteins. Cells are treated with a low-pH 
media change for several hours to induce the E protein conformational changes that lead 
to fusion. After confocal microscopy image acquisition, a fusion index can be 
determined. The number of infected cells, the number of nuclei and syncytia are counted 
to calculate the fusion index (FI = 1- No of infected cells/No. of nuclei). If this fusion 
assay system is deployed, wild-type pSFV-prME can be compared with the MPER 
mutants in C6/36 cells. These results can then be related to results obtained with 
mammalian transfection and infection in PS-EK cells (pCI_NGCprME and NGC DENV-
2). 
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